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INTRODUCTION 
Enterococci are commensals of the gastrointestinal tracts of animals from 
simple invertebrates to humans1.They are known to be relatively avirulent in 
healthy individuals, but have become important opportunistic pathogens, especially 
in hospitalized patients2. They are recognized as opportunistic pathogens and are 
natural inhabitants of the oral cavity, gastrointestinal tract and the female genital 
tract in both humans and animals3. They have emerged as important nosocomial 
pathogens3,4.  
The most frequent infections caused by these organisms include urinary tract 
infections, intra abdominal and intra pelvic abscesses 3,5,6. They also cause surgical 
wound infections, bacteraemia, endocarditis, neonatal sepsis, and rarely 
meningitis5.  
Although about 23 species of Enterococci have been identified, there are two 
main species, Enterococcus faecalis and Enterococcus faecium that are responsible 
for most human enterococcal infections3,4,5. Nevertheless, the incidence of other 
species of Enterococci is underestimated because of frequent misidentification 2. 
Enterococcus was normally ignored by many clinicians in clinical samples 
as it is normal flora7. But now it stands individually in most of the recurrent 
infections and interferes with the healing of wound 7. This organism has been 
reported as the second leading cause of nosocomial urinary tract infections and third 
leading cause of nosocomial bacteraemia in hospitalized patients5. This bacteria 
which is so far considered as a commensal has reached the status of highly virulent 
pathogen 7.The natural ability of Enterococci to readily acquire, accumulate, and 
share extra chromosomal elements encoding virulence traits or antibiotic resistance 
genes lends advantages to their survival under unusual environmental stresses and 
in part explains their increasing importance as a nosocomial pathogens6. Longer 
hospital stay and immunocompromised conditions are known risk factors for 
nosocomial infections like Enterococcal infections6. 
 
Enterococci also show intrinsic ressistance to a number of commonly used 
antibiotics particularly the cephalosporins6. Enterococci are intrinsically resistant to 
many antimicrobial agents and this intrinsic resistance to commonly used 
antimicrobial agents may have allowed them a cumulative advantage for further 
acquisition of genes encoding high level resistance to aminoglycosides, Pencillins, 
tetracycline, chloramphenical,and now Vancomycin6. Moreover, the acquisition of 
high level aminoglycoside resistance and vancomycin resistance has limited the 
therapeutic options available and infections have become extremely difficult to 
manage6.  Multidrug resistant Enterococci are emerging as a leading nosocomial 
pathogen8. 
 
Vancomycin resistant Enterococci (VRE) have emerged as important 
nosocomial pathogens in the last two decades throughout the world9. Since first 
reported in 1988, VRE has rapidly become one of the leading causes of nosocomial 
infection and major growing problems in health care facilities globally10. Emerging 
Vancomycin resistance among Enterocci is a cause of concern as this leads to a 
great difficulty in treating the serious infections caused by them 9.  
 
Vancomycin resistance is undoubtedly the greatest concern, associated with 
severe underlying disease, compromised host defences, indwelling urinary or 
central venous catheters (CVC), prolonged hospitalisation and administration of 
multiple antibiotics especially vancomycin and cephalosporins11. E. faecium is 
more resistant species than E. faecalis and emergence of vancomycin resistance in 
it has caused an increase in frequency of its isolations2.  Nevertheless, the incidence 
of other species of Enterococci is underestimated because of frequent 
misidentification 2. Hence proper identification to species level is essential for 
proper management and prevention of this bacterial infection in any health care 
institution2 
 
The prevention, control and spread of multidrug resistant enterococci require 
coordinated effort from various departments and this can only be achieved by 
educating hospital staff regarding the problem of drug resistance, vigilant use of 
antimicrobials, early detection and reporting by laboratories and immediate 
implementation of appropriate infection control measures. 
 
The above details clearly emphasize a need for isolation and identification of 
Enterococci to species level from various clinical samples so as to determine the 
epidemiological pattern in our hospital. Hence it is an essential part of the 
surveillance system of each and every hospital setup to monitor continuously such 
VRE infections and to assess the antibiotic susceptibility pattern of VRE isolates. 
Assessment of the prevalence and changing trends of VRE infections are of 
immense help in planning infection control measures which should be implemented 
in the hospital and also in the community to reduce the mortality and morbidity 
caused by these VRE infections.In view of the above perspective, the present study 
is carried out in our tertiary care hospital in Chennai, India. 
  
AIM & OBJECTIVES 
 
1. To isolate and speciate the Enterococci from various clinical samples. 
 
2. To detect the virulence factors of isolated Enterococci Species. 
 
3. To find out the antibiotic susceptibility pattern and their emerging resistance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
Enterococci are common inhabitants of   human and animal intestinal flora. 
Infections with Enterococcus species including E.faecalis and E.faecium have 
attained greater clinical importance particularly with the emergence of resistance to 
Vancomycin and they are nowadays mostly associated with nosocomial 
infections12,13. 
 
HISTORICAL PERSPECTIVES: 
 
 In 1899, Thiercelin used the name Entercocccque for the first time in an 
article published from France. The name Entercoccci was proposed to gram 
positive diplococci to highlight its  intestinal origin.
 14,15 
In 1906 Andrews 
and Horder coined the name Streptococci faecalis which caused endocarditis 
fermented lactose and mannitol but not raffinose. The role of Enterococci in 
urinary tract infection was also reported.
14,15  In 1919, Orla &Jensen used 
Streptococci faecium a different teriminology, which differed from 
Streptococcus faecalis by its fermentation pattern
14,15
.  
 In 1937 Sherman separated Streptococci into 4 groups as pyogenic, viridans, 
lactic and enterococcus. Latter term Enterococcus, characterstics of these 
organisims were considered as  growth at 10
0
C and 45
0
C, which even 
survived for 30 minutes at 60 
0
C , shown growth in 6.5% Nacl (sodium 
chloride) and can grew at pH of 9.6 and its ability to split esculin
 14
 
 In 1937 Sherman & Wing proposed third species Streptococcus durans. In 
1955, Enterococci from Gouda cheese was noted and was named 
S.malodoratus (meaning bad odour).
14,16 
In 1959 some motile enterococci 
were noted producing yellow pigment and in 1968 those were named as  
S.faeceum var casseliflavus 
17 
In 1967, Nowlan and Debeil noted  some 
strain of  Enterococci were found to react with Group D as well as with 
Group Q , as they resembled closely with Enterococci from chickens they 
were termed as Streptococcus  avium
14 .   
  In 1970, it was proposed by Kalina that a Genus Enterococci was to be 
established based   on Phenotypic Characteristics & its cellular 
arrangement15. Farrow et al. in 1983 presented biochemical and DNA 
hybridization data indicated that S.faecalis, S.faecium, S.casseliflavus, 
S.avium, S.durans, and S.faecalis var malodoratus were all distinct.  
 In 1984 Schleifer and Kilpper-Balz using  DNA-rRNA and DNA-DNA 
hybridization observed that S. faecalis and S.faecium were very distantly 
related to other streptococci group  including S. bovis, and suggested that  it 
should be transferred to another genus , and it was this  genus name 
“Enterococcus”  was strongly  proposed by Schleifer and Kilpper-Balz 18 
  Later Collins, Jones and Farrow with Schleifer and Kilpper-Balz worked it 
out with similar methodology and the newer names proposed were E. avium,  
E. casseliflavus, E. durans, E. malodoratus, and E. gallinarum. Though it 
was not incorporated into the official Bergey’s nomenclature, but this work 
was cited in Bergey's Manual and considered to prop up the new genus 
creation to include the Enterococcal group of organisms. Further Nucleic 
acid studies used to define other species within the proposed genus 
Enterococcus.
 14  
 
 
HABITAT 
Enterococci present widespread in nature and are found in soil, water, food, 
plants and animals including reptiles, insects, birds & Mammals. Like in other 
animals, In humans also they are predominainantly present in Gastrointestinal tract, 
less commonly inhabitate other sites like genitourinary tract and vaginal cavity. 
Many intrinsic characteristics of Enterococci make them to survive and grow in 
harsh environmentsT. They   are adapted to those ecologically varying complex 
environments which may be enriched with nutrient or even depleted with oxygen.
19  
  They are Gram positive cocci occurring in stool with concentration ranging 
from 10
5 
to 10
7 
CFU/gm19.
 
E. faecalis is more common than rest of the species. 
E.faecium is found with an average count of 10
4 
to 10
5 
CFU/gm of stool 14. 
Enterococci of animal origin may give an atypical reaction in diagnostically 
important carbohydrate reactions. The subsistence of these host related traits might 
provide valuable evidence in the investigation of the probable transfer from animal 
strains to humans14 
TAXONOMY 20,21,22,23,24:     
Kingdom : Bacteria (Cellular) 
Phylum : Firmicutes 
Class : Bacilli 
Order : Lactobacillales 
Family : Enterococcaceae 
Genus :  Enterococcus 
 
Members of the Genus Enterococcus23:   
 E. faecalis, E.faecium, E.avium, E.casseliflavus, E.cecorum*, E.dispar, 
E.durans, E.gallinarum, E.hirae, E.munditi, E.malodoratus, E.pseudoavium*, 
E.raffinosus, E.saccharolyticus*, E.seriolicida, E.solitarius, E.columbae*, 
E.sulfureus*, E.asini and E.haemoperoxidus*.           
   *Are not isolated from human beings. 
Species are grouped on the basis of 16 S rRNA sequencing
25
 
1. Faecium group : E. faecium, E. munditi, E. durans, E. hirae  
2. Avium group  : E. gallinarum, E.casseliflavus  
3. Cecorum group : E. cecorum, E. columbae  
4. Other distinct  :  E.faecalis,E.dispar,E.sulfureus,    
    E.saccharolyticus 
 
 
GENUS DESCRIPTION: 
Enterococci are gram-positive cocci, oval in shape, arranged as pairs or short 
chains26. They are facultative anaerobes, non motile, catalase negative, react with 
Lancefield group D antigen, grow at 10ºC and 45ºC. Grow in broth containing 6.5% 
NaCl, at pH 9.6 and survive heating at 60ºC for 30 minutes, hydrolyse esculin in the 
presence of 40% bile, hydrolyse L-pyrrolidonyl -naphthylamide (PYR) to produce 
pyrolidonyl arylamidase26.  
 Enterococci differ from other Group D faecal Streptococci like S.equinus, 
S.bovis by surviving heat for 30 min at 60ºC, growing in 6.5%NaCl broth, forming 
NH3 from arginine
26. 
 
VIRULENCE FACTORS: 
 Three main groups of virulence factors may enhance the capability of 
enterococci to colonize the gastrointestinal tract and cause disease27. The potential 
virulence factors (Enterococcal secreted factors, Enterococcal surface components) 
identified in Enterococcal isolates and proposed to play a role in pathogenesis are 
as follows 23,27,28 
 
Enterococcal secreted factors: 
The first group, Enterococcal secreted factors, are molecules released 
outside the bacterial cell that contribute to the process of infection. A heterodimeric 
toxin Cytolysin /hemolysin,  secreted by some strains of E.faecalis lyses human, 
bovine, rabbit and equine erythrocytes (but not RBCs of sheep) and 
polymorphonuclear leucocytes & macrophages, play major role in endocarditis and 
endophthalmitis rabbit models23  
Enterococcal proteases-The serine protease (SprE) and gelatinase (GelE), of 
E.faecalis mediate virulence by several mechanisms like modification of immune 
components and degradation of host tissues 27. This enzyme an extracellular zinc-
endopeptidase, capable of hydrolyzing gelatin, casein, collagen, hemoglobin and 
other small biologically active peptides19. 
Extracellular superoxide, by most of E.faecalis and some E.faecium strains 
produced in huge amounts that may increase its virulence in mixed flora abcesses 23. 
An extracellular metallo endopeptidase, Coccolysin secereted by E.faealis strains 
by inactivating the vasoactive peptide –endothelin mediate its  virulence 23. 
 
Enterococcal surface proteins: 
Second groups, Enterococcal surface component, are thought to contribute to 
bacterial attachment to extracellular matrix molecules in the human host 27. 
Aggregation substance –a surface bound protein  encoded by Phreomone 
responsive plasmids which increases its adherence to epithelial cells and increases 
clumping of organisms and thereby facilitating plasmid exchange . In rabbit 
endocarditis model, it also promotes the growth of cardiac vegetations 19,23,. 
The surface proteins – Acm (homologue adhesion of E.faecium) and Ace 
(adhesion of collagen of E.faecalis) are Enterococcal surface components detects 
adhesive matrix molecules (MSCRAMM) which mediate attachment of bacteria to 
host proteins like fibronectin, fibrinogen, collagen27. 
Other surface proteins sharing  similar homology to MSCRAMM playing  
role in bacterial attachment  and in virulence are second collagen adhesion of 
E.faecium (Scm), surface proteins (Fms) of E.faecium, SgrA ( which binds to basal 
lamina components), Enterococcal surface protein (Espfc) of E.faecalis and of 
E.faecium(Espfm) and  EcbA which binds to collagen type V 27, 28 
 Lipoteichoic acid (group D antigen) acts by modulating immune response 
by inducing the Interferon production as well as TNF thus plays its role in virulence 
23 .  Pili are important mediator for bacterial attachment and invasion into the host 
tissue. It is present in both E.faecalis and E.faecium and are thought to be targets of 
immunotherapy27.  
 
Biofilm Formation: 
Biofilm producing bacteria are capable of adherence to damaged tissue and 
plastic surfaces such as medical devices. It helps them for colonization as well as 
increases their capacity to cause infections. Some strains (Mutants) of E. faecalis 
which lack pili have shown attenuated production of biofilm in experimental 
urinary tract infections and endocarditis27.  Polysaccharides may interfere with 
phagocytosis and thus play its role in pathogenicity. E.faecalis some strains 
possesses 3 distinct classes of capsular polysaccharides which are considered to be 
the targets for immunotherapy19,27 
Other virulence factors: 
 The third group of virulence factors has not been well characterized27.  
E.faecalis stress protein Gls24 – play a role in Enterococcal resistance to bile salts 
hence significant in pathogenicity of endocarditis27. hyl Efm- containing plamids 
found in E.faecium , increase the colonizing capacity27. Recently, a gene (AsrR) 
which encodes for oxidative stress regulation has been detected as an significant 
virulence factor of E. faecium. 
PATHOGENESIS: 
Enterococci are opportunistic nosocomial pathogens, infections may arise 
from translocation of its cells from the site of colonization of the gastrointestinal 
system to other host sites and even to the hospital setting 29.  From the site of 
colonization, the microorganism must evade host clearance and produce pathologic 
changes in the host, either by direct toxic activity or indirectly by inducing an 
inflammatory response28.  
Adherence to the host tissue is the first step for Enterococci to act as 
pathogens. During tissue invasion organism faces an environment unlike that of its 
site of colonization by producing higher level of redox potentials, reduced essential 
nutrients, phagocytic attack by leucocytes & other host defense mechanisms. 
Enterococci express factors that permit adherence to host cells and extracellular 
matrix, facilitating tissue invasion, effecting modulation in immune responses, and 
cause toxin mediated damage19. 
 New traits Acquisition like virulence associated genes and their intrinsic 
resistance to the antibiotics that are used commonly, allow them to rise above the 
defense mechanisms of host. These acquired traits along with the acquired 
antibiotic resistance differentiate from the commensals and the virulent pathogenic 
strains. These along with the changed dynamics of host – commensal relationships 
like diminished host immunity, host injury and broad spectrum antibiotic use, 
promote colonization of new niches favoring infections and its dissemination to 
other tissues and environment28. Especially the use of drugs like  cephalosporins 
(broad spectrum antibiotics) which are excreted in bile also active against anaerobes 
and  gram negative bacteria,  which eradicate the challenging  mechanism of 
intestinal flora and also  significantly increases  the suppression of important 
immunological signals like lectin RegIIIγ, which keep Enterococi in low numbers 
usually27. The Enterococci resistance traits exhibit survival advantage for a long 
time in the host or persistent existence in such environment and play a significant 
role as prominent nosocomial pathogens28.   Their clinical significane further 
increased by an important factor that Enterococci can transfer the resistant 
determinants to other Gram positive bacteria 29.  
Because of   bacterial genome sequencing, it is better understood about 
bacterial diversity, virulence, pathogenesis, evolution, and mechanisms of antibiotic 
resistance. For around 560 Enterococcal strains the genomic sequences are 
available at present. It gives new clues regarding the Enterococcal evolution from 
commensal to significant nosocomial pathogens 27. 
CLINICAL INFECTION  
Enterococci are known to cause a wide range of infections, practically 
infecting almost all human systems.  
Urinary tract infections: 
Urinary tract infection (NosocomialUTI) is the commonest  infection caused 
by the Enterococci . They are usually related with anatomic abnormalities of 
genitourinary tract, indwelling catheters, other instrumentation, recurrent UTIs and 
usage of prior antibiotics 27. E.faecium being the predominant species (40%) 
followed by E.faecalis (25%) and other species (35%) being isolated29. In 
differentiating true infection from colonization may be really difficult and the 
factors like presence of leucocytes in urine along with systemic manifestations like 
fever, other local symptoms and signs , and a colony count of  > 105 CFU/ml may 
assist in this regard27,29. Removal of catheter itself may be just enough to eradicate 
this agent. The complications associated with Enterococcal UTI are recurrent 
bacteremias, pyelonephritis and perinephric abcess 27. 
 
Bacteremia and Endocarditis: 
Bacteremia without endocarditis is one of the commonest presentations of 
with Enterococci. Intravascular catheters and other devices are the most common 
sources and others like genitourinary and biliary tracts, pelvic and intra abdominal 
foci, UTIs, wound and bone infections also may contribute to bacteremic episodes. 
Bloodstream infections with E.faecium may carry the worse prognosis because of 
its higher rate of ampicillin and vancomycin resistance leaving fewer therapeutic 
options available27.  The association of Strongyloides hyperinfection syndrome in 
immune compromised individuals is well known. They are important causative 
agents of both community acquired and health care associated endocarditis, ranking 
next to Staphylococci. Malignant and inflammatory conditions of gut and 
procedures involving genitourinary or gastrointestinal tracts act as the source of 
origin. Usually in  Male, elderly, debilitated patients with  other comorbid 
conditions tends to be affected. It can affect both native as well as prosthetic valves. 
Commonly affected valves are mitral and aortic valves.  E.faecalis is isolated more 
frequently in Community associated Endocarditis. Typically presented as a sub 
acute course with fever, malaise, weight loss, cardiac murmur and typical stigmata 
of endocarditis (e.g.petechiae, Roth's spots , Osler's nodes). Common complications 
involved are Heart failure, embolic phenomenon. The most common end organ 
involved being brain in embolic manifestations27. 
 
Intraabdominal, Pelvic and Soft tissue infections: 
Enterococci being a part of gastrointestinal tract commensal can produce 
spontaneous peritonitis in patients with cirrhosis and patients undergoing CAPD 
(Chronic ambulatory peritoneal dialysis). It is usually isolated along with enteric 
gram negatives and anaerobes from clinical samples from pelvic and intra 
abdominal collections27. Enterococci are commonly isolated from soft tissue 
infections, particularly those involving surgical wounds. Enterococci colonizes 
decubitus ulcer and diabetic foot and can be a source of bone infections27. 
E.faecalis is the common species isolated.  
 
Meningitis: 
Only 4% of all meningitis cases caused by Enterococci. The most common 
species isolated is E.faecalis followed by E.faecium.  Spontaneous meningitis is a 
community acquired in patients with many comorbid conditions like renal failure,  
Diabetes, immune suppression , malignancy  and in children with CNS pathology. 
In hospital acquired in the presence of shunt devices it causes Post operative 
meningitis. In both forms clinical features are similar acute course with fever, 
altered mental status and signs of meningial irritation. Complications include 
hydrocephalus, stroke and brain abcess 27,29. 
 
 
 
 
Other infections: 
It also causes neonatal infections like late onset sepsis, bacteremia, 
pneumonia and UTI in the presence risk factors like prematurity, low birth weight 
and indwelling devices. It also causes bone and joint infections. 
 
Health Care associated Infections: 
Health care associated infection also referred to as “nosocomial Infection” or 
“hospital acquired infection”, is an infection occurring in apatient in process of care 
in the health care facility which was not there at the time of admission.The ability 
of Enterococci to survive and disseminate in the hospital setting and their potential 
to acquire antibiotic resistance determinants makes their treatment in critically ill 
patients, really a difficult challenge27. The emergence and spread of VRE and multi-
drug resistant E.faecium isolates increase in rates of nosocomial infections and 
worsens the situation further. Hence it accounts for more post operative 
complications and causing more treatment failure which increases the mortality. 
Enterococci rank third as the causative agents of hospital acquired surgical-site 
infections.  National health Safety Network, USA indicated that Enterococci were 
the second most common cause of health care associated Infections after 
Staphylococus aureus30. Prompt detection of patients colonized with VRE along 
with effective and strict infection control measures can reduce the transmission of 
VRE and help in prevention of health care associated infections31. 
 
 
 
LABORATORY DIAGNOSIS: 
Enterococci can cause serious infections including bacteremia, Endocarditis 
and urinary tract and wound infections. Treatment of infections caused by 
vancomycin resistant Enterococci (VRE) poses great challenge due to its multi drug 
resistance. Hence accurate and prompt identification of Enterococci (including 
VRE & MDR strains) are essential as it will aid in providing better patient care32. 
Collection, transport and storage of specimens: 
The specimens commonly processed are urine, blood, wound exudates and 
secretions from other sites or swab specimens. The standard method of collection of 
these samples is adequate28. Enterococci are nonfastidious, quite resistant to 
unfavorable environmental conditions, no special methods of transport and storage 
of clinical samples are needed28. Specimens can be transported to the laboratory 
using any of the transport medium or on swabs that are kept dry. Enrerococci 
grown on agar slants of Brain heart infusion agar/Tryptic soy agar can be stored for 
several months at 4ºC28. They can also be stored in cryo preservative media at -
20ºC for many years. The preferable methods would be storage as frozen cultures at 
- 70ºC in 10% skimmed milk solution containing 10% glycerol or in heavy cell 
suspensions made in defibrinated rabbit or sheep blood. Enterococcal cultures on 
lyophilization can be indefinitely stored28. 
Direct examination:  
However, only a presumptive report of “presence of Gram positive cocci” 
can be given in case of non sterile specimens. With sterile clinical specimens the 
direct microscopic examination of gram stained smears will be  helpful in 
diagnosing Enterococcal infections28 It becomes  difficult to differentiate 
colonization  and infection especially in urinary tract infection, the presence of pus 
cells will be the key,  where direct examination have significant role27. In 
surveillance programs for detection of VRE, direct detection of Enterococci 
especially VRE from clinical specimens (feces, rectal swab) can be evaluated by 
using conventional and real-time PCR. For rapid detection and identification of 
major pathogens of  nosocomial bacteremia using multiplex real-time PCR assay 
(Light cycler vanA & vanB assay)in  whole blood is available nowadays 30. DNA 
probes which are commercially available also useful for direct identification of 
Enterococci from Blood cultures28. 
 
Cultural Characterstics  
Enterococci are facultative anaerobic organisms and are less fastidious than 
other Streptococci (not requiring CO2 enriched environment). They grow readily on 
ordinary nutrient media, MacConkey’s media and blood agar at a temperature 35°C 
to 37 °C23.  
On MacConkey agar, they form small (0.5 to 1 mm) magenta coloured 
colonies, due to lactose fermentation26.  On blood agar, they form small (1-2 mm), 
circular, translucent and convex colonies with regular margins, usually colonies are 
non-haemolytic, but alpha and beta haemolysis are also observed
26.  One-third of the 
Enterococci species can produce haemolysis on blood agar. 
 
E.durans are β- 
haemolytic. E. faecium is often α-haemolytic. E. faecalis is usually non-haemolytic 
but may be β-haemolytic, which can be used as a differentiating feature. All other 
species are α- haemolytic or non-haemolytic23.  α-haemolysis is not due to the 
cytolysin productionbut due to the production of peroxidases. This haemolysis is 
due to the production of haemolysin, which is transmitted through a plasmid.
   
 
Selective Media  
Selective media usually consists of a selective agent, such as sodium-azide, 
an antibiotic (usually kanamycin or gentamicin) or bile salts or 6.5% Nacl and an 
indicator such as esculin or tetrazolium, incubation at an elevated temperature,also 
has a selective effect (42°C-45°C) Most often used selective media are Bile-
aesculin azide agar23,28,33, KF Enterococcus Agar
33,34
, M-Enterococcus Agar33,  
KAAA (Kanamycin-aesculin azide agar)35, Cephalexin-azetreonam-arabinose 
agar23 
 
GENUS IDENTIFICATION - BIOCHEMICAL REACTIONS 
 Biochemical and physiological tests accomplish identification of 
Enterococcal species.  
 
Presumptive tests for identification of Genus Enterococcus are 
Catalase test  
Like Streptococci, Enterococci are catalase negative, although some strains 
do produce pseudocatalase 16,18,36
 
Bile Esculin hydrolysis test14,37 : 
Enterococci were found to be bile tolerant (40% bile) by Weissenback in 
1918. Esculin is a glycosidic coumarin derivative (6β-glucoside-7-hydroxy 
coumarin). Two moieties of the molecule (Glucose and 7-hydroxy coumarin) are 
linked together by an ester bond through oxygen. For this test esculin is 
incorporated into the medium containing 40% bile. Esculin hydrolysis in the 
medium results in the glucose and aesculitin formation. This esculitin in turn reacts 
with the ferric ions (ferric citrate) to form diffusible black complex. It is considered 
positive, in the presence of 40% bile if esculin is hydrolysed to esculitin resulting in 
the blackening of the medium.  
Positive control - ATCC strain of Enterococcus faecalis  
Negative control -  Streptococcus agalactiae  
 
Growth In 6.5% Nacl broth 14,37  
  In 1978, modified conventional medium of Facklam used by Quadri et al.,
 
They used 1% dextrose  (instead of 0.1% dextrose) with bromocresol purple as pH 
indicator and the results were obtained in 8 to 24 hours.  This test differentiates 
group D non-Enterococcal organisms from Enterococci species, e.g.S.bovis. Brain 
Heart infusion Broth with 6.5% Nacl with a pH indicator is used in the test. The 
positive test is denoted by turbidity and colour change of the indicator.  
 
Positive control   - ATCC strain of Enterococcus faecalis  
Negative control   -  Streptococcus agalactiae  
 
Heat Tolerance Test : 
J.M. Sherman and co-workers demonstrated this property of heat tolerance in 
1937. The methodology of the heat tolerance test has not been standardized. Some 
laboratories heat a sample of broth culture to 60°C for 30 minutes and then streak 
the culture on blood agar plate.
14 ,26,38 
 
PYR Test : 
R.R.Facklam in 1982, intially described this chromogenic enzyme substrate 
test. PYR reagent (α-pyrrolidonyl β-naphthylamide) impregnated in a filter paper 
disc and colour developer (p-dimethylaminocinnamaldehyde) is added separately. 
Results read within 4-5 min39,40. This test provides a presumptive identification of 
group A Streptococci and Enterococci.
39
 
In this test, α pyrroglutamylaminopeptidase enzyme when present , PYR-
substrate hydrolyzed to β- naphthylamide which is then identified by 
p.dimethylaminocinnamaldehyde (colour developer) and forms  bright red colour 
product (red shiff base)
23,40
.
 
This test can be done with PYR broth (Todd Hewitt 
Broth+ 0.01% α – pyrrolidonyl β - naphthylamide) and PYR reagent (0.01% p-
dimethylaminocinnamaldehyde ) The formation of cherry red colour after 4 hours 
of incubation in PYR broth taken as positive and formation of orange or yellow 
colour taken as negative reaction  
Positive control   : ATCC strain of Enterococcus faecalis  
Negative control  :  Streptococcus agalactiae  
 
Litmus Milk Decolarisation test 
This is inexpensive and rapid test done first by Scherl and Blazevic. The test 
organisim was taken in a tube with litmus milk and incubated for 4 hours at 35-
37
o
C, production of white or pale yellow colour is considered as positive and pink 
colour or No change in colour is taken as negative17,41 .  
Positive control  :  ATCC strain of Enterococcus faecalis  
Negative control :  Streptococcus viridians 
 
SPECIATION OF ENTEROCOCCI 
Facklam and Collins proposed the classification of Enterococal species can 
be into 5 physiological groups of species, based mainly on acid production from 
mannitol and sorbose and arginine hydrolysis38. Further speciation is based on acid 
production from 1%  sugars like arabinose, raffinose, sorbitol, pyruvate, sucrose, 
trehalose and reduction of 0.04% tellurite, motility and pigment production 
 Group I – It consists of nine species. They produce acid from sorbose and 
mannitol, arginine is not hydrolysed. E.raffinosus and E.avium are the 
clinically significant species in this group. Others are E.pallens, E.gilvus, 
E.malodoratus, E.saccharolyticus, E.divriesei, E.pseudoavium and 
E.hawaiiensis. 
 Group II – It consists of eight species. They produce acid from mannitol 
only but not from sorbose and arginine hydrolysed. Most of the isolates 
recovered from human sources like E.faecalis, E.faecium, E.casseliflavus, 
E.gallinarum, belong to this group. Others are E.mundtii, E.sanguinicola, 
E.haemoperoxidus, and E.thailandicus. 
 Group III – It consists of six species. They don’t produce acid from sorbose 
and mannitol, but arginine hydrolysed. It includes E.dispar, E.durans, 
E.hirae, E.ratti, E.canintestini, and E.villorum. 
 Group IV – It includes eight species. They don’t produce acid from both 
sorbose and mannitol and arginine also not hydrolysed. It includes 
E.cecorum, E.caccae, E.phoeniculicola, E.aquimarinus, E.asini, E.sulfureus, 
E.silesiacus and E.termitis.  
 Group V – It consists of six species. They ferment only mannitol producing 
acid but not sorbose and arginine not hydrolysed. E.canis, E.columbae, 
E.camelliae, E.hermanniensis, E.moraviensis and E.italicus are included in 
this group. 
CARBOHYDRATE/SUGAR FERMENTATION TESTS  
Mannitol fermentation was considered one important criteria in classification 
of Enterococci in early 1900s.
14 In 1920’s Diebel, Ayers and Johanson did battery 
of test with sugars like arabinose, raffinose, mannitol, sorbitol, sucrose, lactose, 
maltose, trehalose, glycerol, inulin, and salicin along with other tests to speciate 
Enterococci.  But their classification did not included the species faecium, equines 
and bovis. 
R.R. Facklam in 1972 did a battery of 26 physiological tests for 
Enterococcal speciation. In this classification, faecium, casseliflavus, avium, or 
equinus species were detected
42
. Pyruvate fermentation, sorbose fermentation and 
arginine dihydrolation were added to the series by Gross in 1975. Following which 
in 1989, M.D. Collins and R.R.Facklam added  the above three tests, along with a 
battery of  14 tests (from the classification of R.R. Facklam in 1972) to give a 
modified classification scheme  of speciation by using conventional tests.
37 Kathryn 
L. Rouff et al., later in 1990, with the help of Facklam modified classification 
scheme they identified most of all the currently described species
43..Enterococci 
never produce gas as it lacks Kreb’s cycle and respiratory chain. Fermentation test 
is done in brain heart infusion broth with 1% carbohydrates.Test organisms are 
inoculated and incubated for 24 hours at 35-37
o
C and examined upto a week. 
Indicators used are bromothymol blue, bromocresol purple or Andrade's indicator. 
23, 26   
 
Arginine Test 
23,26
 
In 1975, Kathryn Gross, observed that arginine hydrolysis can be used as one 
of the reliable test for Enterococci speciation
43
. In Arginine hydrolysis, arginine 
converted to citrulline is a dihydrolase reaction, where amino group is removed 
from arginine. Citrulline is then converted to ornithine, which undergoes 
decarboxylation and form putresciene.As decarboxylation occurs under anaerobic 
conditions tubes should be over layered with (1cm) liquid paraffin or sterile mineral 
oil.The medium turns yellow in initial stages of incubation because of small amount 
of dextrose getting fermented.Later due to the decarboxylation once the amines are 
formed, it returns to original purple colour.Moellers decarboxylase media is 
preffered media for this test.
 
 
Positive control  : Enterobacter cloacae  
Negative control :  Klebsiella pneumoniae  
Pyruvate Fermentation: 
This is another important test used for Enterococci speciation. to 
differentiate E.faecalis and E.faecium. Overnight culture of test organisim was 
inoculated onto Pyruvate broth (bromocresol purple as indicator) and incubated for 
24 hrs at 35-37
o
C upto 7 days23 
Positive control  :  ATCC strain of  Enterococcus faecalis 
Negative control  : ATCC strain of  Enterococcus faecium
    
 
Motility - is method for identifying the motile Enterococci like E.casseliflavus and 
E.gallinarum determined by hanging drop, modified motility semisolid media, and 
wet mount preparation
44
  
Pigment production – E.casseliflavus and E.munditi produces yellow pigment and 
it can be detected by growing the organisim in tryptic soya agar and it is observed 
using  a cotton swab by touching up the growth from the culture plate.
44  
OTHER TESTS  
 
Potassium tellurite Reduction 
Diebel in 1964 observed reduction of 0.05% potassium tellurite as one of the 
physiological conventional tests to differentiate Enterococci. Facklam in 1971 and 
in 1989
18 
employed 0.04% potassium tellurite in blood heart infusion agar 
(defibrinated blood) as one among the batteries of tests used to speciate 
Enterococci
43
. Conventional test method of Facklam and Collins was followed by 
Kathryn, L. Rouff et al., and they observed the ability of certain strains of 
Enterococci to grow and able to reduce potassium tellurite (0.05%) prepared in 
Todd Hewitt Broth. It was detected by blackening of the medium.  
 
 
Voges-Proskauer Test  
The production of acetyl methyl carbinol was tested for certain Enterococcal 
strains by Susan S. Fertally and R.R. Facklam in 1987 
39. Cobelentz method is 
accepted method for Enterococci. After 24-48hrs incubation to glucose phosphate 
broth with test organism addition of 0.6ml of 5% alpha naphthol followed by 0.2ml 
of 40% potassium hydroxide in that order the appearance of red colour within 15 
min considered as positive result.
36  
Some tests like growth of Enterococci at 10 and 45 
o
C , Sodium Hippurate 
hydrolysis, and 0.1% tetrazolium  reduction are other tests satisfied by some 
Enterococcal strains
26 
COMMERCIAL IDENTIFICATION SYSTEMS-  
 Manual, semiautomated and automated systems like API 20S, API Rapid 
STREP, Rapid ID32 STREP, BBL Crystal  gram positive ID system, Gram positive 
identification card of Vitek system, RAPID ID STR, MICRO SCAN Gram Positive 
Breakpoint Combo panel etc. are available. These are reliable for the detection of 
most common species E.faecalis, E.faecium and to a lesser extent other species of 
Enterococci44. 
  
  
TYPING METHODS 45,46 
Method Principle 
Discrimination / 
reproducibility 
Applications 
Ribo 
typing 
Hybridization of labelled 
rDNA with digested 
genomic DNA 
Medium / Good  Too low discrimination for outbreak 
analysis (short term epidemiology) 
RAPID/ 
repPCR 
PCR with random 
primers or primers 
binding to repetitive 
target sequences 
medium / 
insufficient - good 
Partly suitable for „in house“ 
outbreak analyses; provided with 
commercial kits (DiversiLabTM) 
AFLP Length polymorphisms 
in genomic PCR 
products 
Good / good–very 
good 
Exchanged by MLST due to better 
data portability and discriminatory 
power 
PFGE Genome-based macro 
restriction analysis 
Excellent/ good–
very good 
Still “Gold-Standard” for outbreak 
analyses; not suitable for long term 
epidemiology analyses 
MLST DNA sequence 
comparisons of 
housekeeping genes 
good – very good / 
excellent 
„Gold Standard“ for population-
based analyses; expensive and 
laborious, too less discriminatory for 
outbreak analyses 
MLVA Fragment length 
polymorphisms in 
genomic repeat regions 
good – very good/ 
very good 
Suitable for population-based 
analyses; too less discriminatory for 
outbreak analyses 
vanA 
cluster 
typing 
Different schemes exist 
based on amplification, 
digestion, sequencing3 
good – very good / 
very good 
Only suitable for specialist analyses 
and in combination with basic 
techniques (PFGE, MLST, MLVA) 
Plasmid 
typing 
Analysis of the plasmid 
content and composition 
Limited / very 
good 
Dependent on the corresponding 
question; suitable for analysis of 
“plasmid hospitalism” and for 
enhancing MLST/MLVA analysis’ 
results 
 
 Legend: AFLP, Amplified-Fragment Length Polymorphisms; MLST, Multi-
locus Sequence Typing; MLVA, Multiple Locus Variable Number of Tandem 
Repeat Analysis; NGS, Next Generation Sequencing (synonymous for various 
techniques such as 454, illumina, ion torrent); PFGE, Genomic macrorestriction 
analysis in Pulsed-field Gel electrophoresis.  
The pace with which MALDI –TOF MS that can scrutinize bacterial isolates 
for detection purposes and potentially for relatedness makes it as choice of 
alternative genotypic detection methods. It involves Low turnaround time, Less 
intensive labor47. 
EPIDEMIOLOGY  
Enterococci are part of the normal intestinal flora in humans. The 
predominant species, E. faecalis and E. faecium, are the rising and leading causes of 
nosocomial infections
14,23. 
UTls is the commonest Enterococcal infections among humans and they are 
commonly associated with the structural abnormality or instrumentation of the 
urinary tract.  Intra abdominal and pelvic wound infections, bacteremia are the 
second and third most common infection of Enterococci respectively23.  
E. faecalis the most common species isolated from nosocomial infections, 
the isolation of E. faecium has rised considerably in the past two decades. In reality 
E.faecium at present is nearly equal to E. faecalis as an agent of etiology in 
hospital-associated infections. This fact is more significant, as E. faecium is 
considerably the challenging and most resistant species among Enterococci to 
treat27.  
Enterococci are important pathogens because of their resistance to multiple 
drugs. All Enterococci have intrinsic low-level resistance or relative resistance to 
penicillins, cephalosporins, aminoglycosides etc  
In the past few years a remarkable increase in the Vancomycin resistant 
Enterococci has been reported. Between 1989 through 1993, nosocomial infection 
(due to VRE) has increased from 0.3% to 7.9% reported by National Nosocomial 
Infection Surveillance System, CDC.  This was reported due to a rise in 
vancomycin resistant enterococci infections in intensive care units (ICU)48.  
Risk factors for enterococcal infections are long duration of hospital stay, 
patients with indwelling catheters, serious underlying diseases,  
immunosuppression (oncology and transplant patients), renal insufficiency, 
prolonged antibiotic therapy causing selective antibiotic pressure, particularly with 
broad-spectrum antibiotics like cephalosporins, imipenem, ciprofloxacin and 
aminoglycosides 
48
.  
Both colonisation and infection of Enterococci expressing multi drug 
resistance occur worldwide. It is common in almost all patients those who are 
colonized or infected with vancomycin resistant Enterococci or multidrug resistant 
exposed to previous use of antibiotics. In Europe the use of glycopeptides 
(avoprocin) in animal feeds appear to be the key contributor to the emergence of the 
Vancomycin resistant Enterococci.
48 
 
In India, vancomycin resistance among the Enterococci is emerging. Various 
authors in their prior studies have reported prevalence ranges                  from 1-
8.7% 49,50.  
ANTIBIOTIC THERAPY 
The most active among the β-lactams, are the aminopenicillins (amoxicillin, 
ampicillin) and ureidopenicillins (i.e., piperacillin); next active are penicillin G and 
imipenem27. For E.faecium, a combination of high-dose ampicillin plus an 
aminoglycoside has been suggested. For synergistic therapy only two 
aminoglycosides, Streptomycin and Gentamicin are recommended to treat severe 
Enterococcal infections. Tobramycin should never be used against E. faecium,   use 
of amikacin is discouraged and monotherapy with aminoglycoside is not effective. 
An alternative to β-lactam drugs, Vancomycin is used for the treatment of 
E.faecalis infections but is also less useful against E. faecium as resistance becomes 
common27. Cephalosporins are inactive against Enterococci except ceftobiprole for 
E.faecalis infections. For the treatment of urinary tract infections single agent like 
nitrofurantoin, fosfomycin, ampicillin or amoxicillin can be used27. 
Linezolid and Quinupristin/Dalfopristin are FDA approved drugs used in 
some VRE infections, both are bacteriostatic drugs and used as an alternative to the 
standard drugs. 
ANTIBIOTIC RESISTANCE  
Major reasons why Enterococci survived in hospital setting (nosocomial 
infections)  is their intrinsic resistance to many commonly used antibiotics and their 
ability of acquiring resistance to most of the currently available antibiotics, either 
due to mutation or may be by reciept of genetic material by transfer of Plasmids & 
transposons48. 
Antimicrobial resistance can be either inherent or acquired14 
 INHERENT OR INTRINSIC PROPERTY  
The term intrinsic resistance is used to denote resistance characteristic shared 
by whole species exhibited in almost all the strains of that species. The genes for 
intrinsic resistance reside on chromosomes.   
The various intrinsic traits expressed by Enterococci are:  
 Resistance to β-Iactams, semisynthetic penicillinase resistant penicillins, 
cephalosporins  
 Resistance to low levels of aminoglycosides  
 Resistance to low levels of clindamycin.
14 
 
β – Lactams  
The reason for intrinsic resistance to penicillin is due to the over-production 
of low affinity penicillin binding protein (PBP)14,48. The low affinity binding 
protein usually involved is PBP-5 for penicillin, ampicillin and other β lactams, 
including cephalosporins. The MIC is 2-8μg /ml for pencillin in E.faecalis and 16-
32 μg/mg in E.faecium. Enterococci are moderately susceptible to ticarcillin and 
carbenicillin and are resistant to penicillinase resistant semisynthetic penicillins and 
cephalosporins. Imepenem is more active against E.faecalis but are bacteriostastic. 
Aminoglycosides  
Resistance is predominantly due to the presence of the inactivating enzyme, 
2"- phosphotransferase-6"-acetyl transferase conferring resistance to gentamicin, 
tobramycin, netilmicin, amikacin and kanamycin. Hence resistance to gentamicin 
may be a good predictor of resistance to other aminoglycosides except streptomycin 
where resistance is due to adenyl transferase (ribosomal resistance)
14. 
MIC for streptomycin is 250 μgm/ml and for gentamicin and tobramycin 8 
μg/ml to 64 μg/ml. MICs of aminoglycosides like, kanamycin, tobramycin, 
netilmicin for  E.faecium are higher than other Enterococcal species.  E.faecium has 
a chromosomally encoded acetyl transferase that may present the resistance to all 
amino glycosides .The synergistic activity of Pencillin and Vancomycin along with 
Aminoglycosides is due the increased uptake of these agents in the presence of cell 
wall synthesis inhibitors.  
HLGR has the same mechanism but it is acquired by transmissible plasmids. 
Clindamycins  
Another important feature of enterococci is their resistance to clindamycin and 
lincomycin. MICs for most strains are 12.5 to 100 μgm/ml. .
14 
 
ACQUIRED RESISTANCE  
 This resistance results from either a mutation in existing genes or insertion of 
new genes. Acquired resistances are to the following drugs:  
Chloramphenical, Erythromycin, Tetracyclines, High levels of clindamycin, 
High levels of aminoglycosides, Penicillin by means of penicillinase, 
Fluoroquinolones, Vancomycin  
 Fluoroquinolones resistance may to be due to mutation while resistance to 
other agents listed above can occur by acquisition of new DNA (transposons, 
plasmids)
14,23.  
 This acquisition of new DNA occurs by transduction or conjugation and the 
mechanisms of such acquisitions are   
Broad host range plasmids, Here transfer occurs among Enterococci or with 
species of Streptococcus, Staphylococcus, Bacillus subtilis and others. These 
plasmids may be the reason for sharing of resistance genes between the 
Staphylococci and Enterococci.
14, 23 
 
Narrow host range plasmids, Here, the transfer is found only in E. faecalis so 
far. These plasmids respond to pheromones, from recipient cells, by producing 
aggregation substance. This substance causes characteristic and grossly appearing 
clumping between donors and recipient cells
14,25 
 
Conjugative transposons, The test-studied transposon is Tn 916, which mediates 
tetracycline resistance14. 
PENICILLIN RESISTANCE WITHOUT Β-LACTAMASE  
Existence of Enterococci with incresed penicillin resistance with MIC 
>25μgm/ml may be because of  similar but increased intrinsic resistance or due to 
low affinity pencillin binding proteins or may be because of  acquired resistance. 
HIGH LEVEL AMINOGLYCOSIDE RESISTANCE (HLAR)14 
This Plasmid mediated resistance is due to enzyme 2 phosphotransferase and 
6’ adenyl transferase. Resistance to gentamicin is due to the activity of 3’ 
phosphotransferase and results in, resistance to all other aminoglycosides except 
streptomycin. Streptomycin resistance is due to the activity of adenyl transferase. 
Hence Gentamicin and Streptomycin should be tested individually to predict the 
resistance to aminoglycosides. 
Two types of Resistance mechanisms 
a) Low permeability to aminoglycosides causes moderate level resistance (MIC 
64-500μg/ml), It is surpassed by synergism with cell wall active agents and 
effective in treatment strategy. 
b) Inactivating enzymes production like acetyl transferase and adenyl 
transferase and also ribosomally mediated resistance causes high level 
resistance (MIC - 2,000μg /ml). 
Resistance to streptomycin - Altered ribosomal target and modifying enzymes  
Resistance to gentamicin – Mostly by modifying enzymes. 
 
 Resistance to either cell wall active agent or aminoglycoside both may lead 
to acquiring  resistance to the synergistic killing of Enterococci when used in 
combination therapy and therefore poses a major  therapeutic problem. Hence 
earlier detection of resistance to both these agents is significantl for the assessing 
the synergy effect of the combination therapy  
 
Screening Tests  
 Following are the various screening tests that are recommended and 
available for detecting High Level Aminoglycoside Resistance. 
 
Agar Screening Method – Murray et al. used heavy inoculums streaking onto  the 
brain heart infusion agar containing 1000 μg of gentamicin and 2000 μg of 
streptomycin per ml. They observed growth on the plate corresponds with high-
level resistance among the strains. 
High content discs method: High content disc to identify HLAR. Gentamicin 
(120 μg) and streptomycin (300 μg) used. The zone of inhibition is interpreted 
according to CLSI 2015 guidelines.  
Determination of MIC: By Broth dilution Method or by E-strip method. 
 
VANCOMYCIN RESISTANT ENTEROCOCCI (VRE)  
Vancomycin-resistant E.faecalis and E. faecium were reported first in 1988 
in England. Emergence of Enterococcal resistance to vancomycin is one of the 
most alarming news in history of microbiology. It is reported to be inducible 
resistance and can be transferable by conjugation.  
Vancomycin is one of the two glycopeptides currently in use to treat 
Enterococcal infections, the other one being Teicoplanin. Vancomycin resistance 
can be divided into high level (MIC ≥ 64 mg/ml) and low level (MIC ≥32 mg/ml) 
and there are various phenotypes. 
The mechanism of action of Vancomycin is inhibition of transglycolysation 
and transpeptidation of the pentapeptide units – (the last step in peptidoglycan 
synthesis) and thereby interfering with the synthesis of cell wall in bacteria29.  
Based on phenotypic and genotypic characteristics they are classified s as 7 
types of glycopeptides resistance – vanA, vanB, vanC, vanD, vanE, vanG & 
vanL23,28. Some of them even have subtypes also. The most clinically related 
phenotypes are vanA and vanB and they   are generally related with E.faecalis and 
E.faecium and vanC is intrinsic to E.casseliflavus & E.gallinarum23.  
The genotype explains the gene clusters which encode the enzymes that are 
concerned in the generation of their structural components. These are the diverse 
peptidoglycan precursors that have reduced binding affinity for glycopeptides 
(vancomycin, teicoplanin or both). Phenotypic resistance may be the result of these 
alteration in structural components. The glycopeptide- susceptible strains have, 
“Dalanyl- D-alanine” depsipeptide in their cell wall, as the terminal end of 
peptidoglycan side chains. The antibiotic inhibits the cell wall synthesis by binding 
to this depsipeptide. In glycopeptide – resistant strains, this depsipeptide is replaced 
with “D-alanyl-D-lactate” (vanA, vanB, vanD) or “D-alanyl-Dserine” (van E, 
vanG) 23. Nine different types of glycopeptide resistance operons (vanA, vanB, 
vanC, vanD, vanE, vanG, vanL, vanM, and vanN) have been expressed in 
Enterococci of which vanA, vanB are the most clinically important51,52. 
vanA –encoded by van A gene. It is an inducible high level resistance to both 
vancomycin (MIC 64-1,000 μg/ml) and teicoplanin (MIC 16-512μg/ml)23,48,51. It is 
located on the transposon Tn154651,53. The altered gene product is “D-alanine-D-
lactate”. It is frequently encountered in E.faecalis, E.faecium 
vanB –Encode by van B gene. It is an acquired inducible, resistance (variable level) 
to vancomycin (MIC 4-1,024μg/ml), but susceptible to teicoplanin (MIC 0.5-
1μg/ml)51,23. The gene is mediated by trasposons Tn1547, Tn1549, Tn5382 and they 
are located in plasmid51. The gene product is “D-alanine-Dlactate”. It has 3 
subtypes (vanB1-B3) and is distributed in E.faecalis, E.faecium. 
vanC- It is Encoded by constitutive expression of van C gene, which is located in 
chromosome and exhibits intrinsic low level vancomycin resistance (MIC 2-
32μg/ml) and susceptible to teicoplanin (MIC 0.5-1μg/ml)23,51. The end product is 
“D-alanine-D-serine” and has 4 subtypes dispersed in E.gallinarum (C1) and 
E.casseliflavus (C2-C4). 
vanD – It is encoded by constitutive expression of van D gene, mediated by 
chromosome, moderate level vancomycin resistance (MIC 64-128μg /ml) and to 
teicoplanin (susceptible / resistant)  (MIC 4-64μg /ml) . The product is “D-alanine-
D-lactate” and is commonly found in E.faecium and rarely in E.faecalis, E.avium 
and E.gallinarum. 
vanE– They are encoded by van E gene which is located in chromosome, results in 
inducible low level  vancomycin resistance (MIC  16 μg/ml) , susceptible to 
teicoplanin (MIC 0.5μg/ml). “D-alanine-D-serine” is the end product and is found 
in E.faecalis. 
vanG– They are encoded by van G gene, located in chromosome, results in 
inducible low level resistance to Vancomycin (MIC 16 μg/ml), susceptible to 
teicoplanin (MIC 0.5μg/ml). “D-alanine-D-serine” is the end product and is found 
in E.faecalis. 
 The identification of the different genotypes is crucial for therapeutic and 
infection control purposes. 
Vancomycin Dependent Enterococci: These were first expressed in 1994 that 
some strains of Enterococci grow well only in presence of Vancomycin. If 
vancomycin is not present VRE retain their ability to make D-alanine-D-alanine 
depsipeptide and they proceed to grow normally. VDE strains are unable to make 
this D-alanine-D-alanine depsipeptide. Hence the presence of vancomycin provide 
these strains a chance to use D-alanine-D-lactate as cell wall constituent. VDE 
strains are from both E.faecalis, E.faecium but relatively uncommon23,54. 
Vancomycin Variable E.faecium: Vancomycin susceptible E.faecium following 
drug exposure to Vancomycin becoming resistant. They potentially posing 
significant challenges in both clinical as well as microbiological aspects55. 
 
 
RISK FACTORS ASSOCIATED WITH VRE: 
The risk factors related with colonization and infection with VRE have been 
studied. The various risk factors are as follows27,30,48,56,57: 
 Presence of immunosuppression(bone marrow transplantation/ haematologic 
malignancy) 
 Presence of co-morbid conditions like diabetes, high APACHE (Acute 
Physiology and Chronic Health Evaluation) score, renal failure, malignancy. 
 Prolonged stay in hospital and hospital transfer within the hospital. 
 Residence in a long term care facility, contact with another infected / 
colonized patient. 
 Previous exposure to broadspectrum antibiotics like cephalosporins, 
vancomycin. 
 Invasive procedures,  use of enteral tube feeding / sucralfate 
 Contaminated medical equipment Exposure. 
 Exposure to heath care personnel providing nursing to a known VRE patient. 
 
 
COLONIZATION AND INFECTION: 
Colonization of the gastro intestinal tract seems to be the first step in process 
of infection. In the majority of occasion, isolationof VRE is mostly from colonized 
patients rather than infected individuals. It is expressed in such a way that for every 
infected patient there could be around 10 colonizers48. Usually colonization 
involves gastrointestinal tract, perineal skin and rarely oral cavity and other sites. 
The sites involved in VRE infections are bloodstream, surgical wounds, intra-
abdominal sites, intravascular catheters, prosthetic devices, and urinary tract48. VRE 
infections usually occur in debilitated and critically ill hospitalized patients. In their 
prior studies many authors have reported mortality rate ranging from 46%-70% 
among patients with VRE infetions48. The mortality seems to be higher in patients 
with prolonged VRE bacteremia such as neutropenic, liver transplant recipients and 
patients with chronic renal failure. Differentiation between colonization and 
infection,  is difficult, as often these infections are polymicrobial and are isolated 
along with various known pathogens48. 
SOURCE OF INFECTION AND TRANSMISSION OF VRE: 
The source of infection could be Endogenous or Exogenous. Endogenous 
from patients own gastrointestinal tract from prior colonized individuals. 
Exogenous from  contaminated environmental surfaces and contaminated medical 
devices – linen,bed rails, bed pans, doorknobs, glucosemeters, IV pumps, ECG 
monitor,blood pressure cuffs, and stethoscope. VRE are resistant to dessication and 
extreme temperatures and hence persists for days to months. Contaminated food 
products act as a reservoir in non hospitalized individuals. 
The transmission of VRE is through the contaminated hands of healthcare 
workers in hospital settings (nosocomial VRE infections) and coming  in contact 
with contaminated surfaces  and contaminated equipments48,57 
SCREENING METHODS:  
Disc diffusion method:  
 To a lawn culture of Enterococci (0.5 Macfarland standard) Vancomycin 
30μg disc applied  in 5% MHA blood agar and interpreted according to the CLSI 
2015. 
Agar Screening Method  
 Presumptive identification of VRE is done by vancomycin screen agar 
containing 6μg of vancomycin per ml of media.  
Detection of minimum inhibitory concentration (MIC)  
 Confirmation is always by determination of minimum inhibitory 
concentration (MIC) of vancomycin and teicoplanin for the suspected VRE isolates. 
Broth dilution method or agar dilution method followed.  Epsilometer tests and 
automated method for detection of MIC and interpreted according to CLSI 
guidelines 2015. 
Agar Dilution Method: Mueller Hinton Agar was supplemented with various 
concentration of Vancomycin and overnight bacterial culture isolate was adjusted to 
0.5 Mcfarland turbidity standard. 10μl of culture isolate was spot inoculated onto 
the plates.  Then the culture plates were incubated for 24 hours at 37ºC and 
observed for growth. MIC was taken as minimum concentration of Vancomycin 
that inhibit growth of Enterococci.  
Enterococci MIC for Vancomycin interpreted as follows: 
 ≥32μg/ml - Resistant, 8-16μg/ml- Intermediately Resistant and ≤4μg/ml-Sensitive 
E-test:  Epsilometer test strip applied on  to lawn culture of Enterococci in Mueller 
Hinton agar and incubated at 37ºC  for 18 -24 hrs  examine it. MIC ≤4μg/ml 
considered as Sensitive,  8-16μg/ml  taken as Intermediately Resistant and 
≥32μg/ml considered as resistant as per CLSI guidelines 2015. 
 
Molecular methods  
 Polymerase chain reaction for the amplification of genes of vancomycin 
resistance - vanA, vanB and vanC, either conventional or multiplex PCR or by 
DNA hybridization probes. Use of Cepheid Expert vanA/vanB assay on inoculated 
enriched broths with adjusted threshold value for PCR positivity can be considered 
a useful tool for detection of vanA/vanB58 
Treatment of VRE infections: 
The therapeutic options for serious VRE infections are synergistic  therapy 
with cell wall active agents high dose (ampicillin) and an aminoglycoside (provided 
no acquired resistance seen for both of these agents) . Other therapeutic options are 
as follows. 
Linezolid – It is a bacteriostatic drug, belongs to oxazolindones it is FDA approved 
drug for treatment of VRE infections of E.faecalis, E.faecium. It binds to the 
ribosomal peptidyl transferase center and stops bacterial growth by protein 
synthesis inhibition53. It is recommended only as an alternative to other agents, play 
a vital role in the endovascular infections and in meningitis27. Also effective in 
MRSE, MRSA, VISA and VRSA. 
Quinpristin-Dalfopristin – It is a bacteriostatic drug, parentral semisynthetic 
streptogramin type A and B. it is FDA approved and active against E.faecium only 
and not against E.faecalis27. It is because of presence of an ATP binding cassette 
(ABC) protein homologue designated Lsa, which is likely to act as an efflux pump 
for this compound29. Mechanism of action is it binds to 50 S ribosomal subunit and 
blocks the translation. Effective in treatment of MRSA, MRSE, VRSA & VRE 
(E.faecium only)53. 
Daptomycin- It is a cylic lipopeptide active against both E.faecalis and E.faecium, 
it is not  FDA approved for VRE treatment in E.faecium29. It causes rapid 
membrane polarization triggering calcium dependent rapid efflux of potassium ions 
and thereby inhibiting RNA, DNA and Protein synthesis53. It is approved for VSE 
skin and soft tissue infections59. Only in therapeutic failure of the commonly used 
other agents it can be used. Also can be used in MRSA & VRE peritonitis53,61. 
Tigecycline-It is a glycylcycline It is FDA approved for treatment of abdominal 
infection and complicated skin and soft tissue infections (CSSSI’s) and complicated 
intra abdominal infections.29,53,60. Binds to 30S ribosome, blocks entry of transfer 
RNA and prevents protein synthesis by delaying incorpoaration of aminocids into 
peptide chains. Also can be used in treating MRSE, VRE, Meropenem resistant 
Klebsiella, Acinetobacter and ESBL producing      Escherichia coli. 
Ortivancin- It is a Lipoglycopeptide, recently approved by FDA, used in skin and 
soft tissue infections, showed good in vitro activity has a promising role in 
treatment of VRE in future27,31. They disrupt cell wall synthesis and cell membrane 
integrity. It is useful to treat MRSA, VISA, VRSA and VRE53. 
Tedizolid- It is a Oxazolidinones approved recently by FDA to treat acute bacterial 
skin & soft tissue infections. It showed good in vitro activity against VRE31. 
MULTI DRUG RESISTANCE ENTEROCOCCI: 
In recent years, some strains have acquired high level resistance to multiple 
antibiotics including aminoglycosides, ampicillin and vancomycin.  Vancomycin 
resistance is of particular concern because of treatment difficulties and because of 
the potential for this plasmid mediated vancomycin resistance trait to be transferred 
to other microorganisms. In the event methicillin resistant S. aureus were to acquire 
vancomycin resistance genes from Enterococci, this pathogen would become 
virtually untreatable with the current antibiotics 
61
. In recent studies it has been 
observed that drugs which are used in treatment of  VRE, like Linezolid, 
Daptomycin, Quinipristin / Dalfopristin, Tigecycline also has developed resistance. 
PREVENTION AND CONTROL MEASURES: 
CDC - Hospital Infection control practices advisory committee has given 
certain guidelines and recommendations to be followed for the prevention of spread 
of VRE 
 Inappropriate use of vancomycin being a major risk factor for VRE infection 
and its colonization and also for emergence of vancomycin resistant 
Staphylococci. Hence prudent use of vancomycin is recommended. 
 All  health care personnel should be educated about the acceptable or  
appropriate use of  vancomycin (MRSA treatment, implantation of prosthetic 
devices following  major surgical procedures, severe antibiotic associated 
colitis as a second line agent ) 
 Awareness for standard precautions (PPE), should be created among all health 
care workers. Standard precautions are the basic infection control precautions 
which should be followed in any setting where health care is delivered and are 
used to prevent infection from the health care workers to patients and vice 
versa. 
 Education of the Health care personnel and patient care givers about the impact 
and epidemiology of VRE infections. 
 For early detection of colonization of VRE effective implementation of 
surveillance procedures (feces cultures) should be done. 
 Infection control procedures are aimed to limit cross contamination, isolation of 
those known VRE colonizers and patients and very strict adherence to hand 
washing as it’s alone can slow down the spread and transmission of VRE 
among hospital setting to a considerable extent. 
 Antibiotic stewardship programs to be conducted and awareness to be spread to 
strictly adopt antibiotic policy which advocates the rational use of antibiotics.  
  
MATERIALS AND METHODS: 
 
 The present study was conducted in Department of Microbiology in 
Government Kilpauk Medical College and Hospital, Chennai, India. 
Study Population : Patients attending outpatient department and inpatients of  
    Govt.  Kilpauk Medical College and Hospital, Chennai. 
Study Period :  January 2015 to December 2015 - one year  
Study Design :  Cross sectional study 
A total of 240 Enterococci isolates recovered from various clinical 
specimens were processed for further study. Those clinical specimens such as urine, 
pus, blood, High vaginal swab,  tissue fluids and feces  were obtained from both 
sexes  in all age groups of patients submitted to the microbiology laboratory and 
were analyzed for further study 
The study was approved by our Institutional Ethical Committee. 
 
INCLUSION CRITERIA :  
 All non duplicate Enterococci isolates taken from various clinical samples 
like urine, pus, blood, high vaginal swab, tissue fluids, faeces. 
EXCLUSION CRITERIA:  
 Isolates other than Enterococci isolated from various clinical samples  
METHODOLOGY  
 All specimen brought were subjected to the following  
Direct microscopy62  
 Smears were made from all specimen except the blood. Gram staining was 
done. Observed for the presence of pus cells and Gram positive cocci, occurring in 
ovoid pairs or in short chains.  
Culture  
The specimens were inoculated on to Blood agar, Nutrient agar and 
MacConkey agar.36,63,64,65. They were also inoculated into Bile esculin agar 
medium36,66. Urine specimen was processed for semiquantitative culture
65. It was 
inoculated onto the Cystine lactose electrolyte deficient (CLED) media 65,67. Media 
containing plates after inoculation were incubated and looked for growth. They 
were incubated at 37°C for overnight. 
Plates were examined for:  
 Blood Agar  :  Presence of small, nonhemolytic or α hemolytic  
      colonies 
 Nutrient Agar : Presence of small, 0.5-1mm colonies 
 MacConkey agar : Presence of deep pink magenta colored colonies  
 Bile Esculin Agar : Blackish discoloration of the medium 
 CLED media  : Small, yellow colored  colonies  
 In case of urine sample, a semi-quantitative calibrated loop technique was 
used to isolate the organism. One loopful holding 0.01 ml of clean catch midstream 
urine sample that was not centrifuged was inoculated onto the surface of Cysteine 
Lactose Electrolyte Deficient agar. The culture plates were incubated under aerobic 
conditions for 18-24 hours at 370 C.  
 Using colony counter the colonies was counted and the numbers of colony 
forming units were multiplied by 100 to find out the number of microorganisms 
present per millilitre of urine.  Only the significant counts were processed in which 
showed 10
5
cfu/ml68,69. Lower counts were processed based on the clinical history of 
patient. The suspected Enterococcal isolates grown on the primary plating media 
such as blood agar and MacConkey agar were selected for further identification. 
Following tests are done for Presumptive identification:  
Colony smear36,64,66,70:  
 Gram staining was done with a smear prepared from the colonies and 
observed for the presence of Gram positve cocci arranged in pairs and short 
chain16,18,36. Gram Staining was done along with the Controls  
Positive control   : Staphylococci ATCC 25923  
Negative control   : Escherachia coli ATCC 25922  
 It is again subcultured onto nutrient agar for catalase test and blood agar for 
demonstration of haemolysis.  
Catalase test 18,36,64,70:  
 A part of a colony was taken with the help of small glass rod and immersed 
in a test tube containing 3% hydrogen peroxide. The catalase test was done along 
with controls. A rapid and sustained effervescense due to the presence of nascent 
oxygen was taken as positive result26. 
Positive control   :  Staphylococcus aureus ATCC 25923  
Negative control   :  Enterococcus faecalis ATCC 29212  
Enterococci are catalase negative or pseudocatalase positive16,18,36 
Bile Esculin test14,37,65,66,70:  
 The isolates were inoculated on to the bile esculin agar and incubated at 
37°C for 24 -48 hrs. A positive test was indicated by the growth of black coloured 
colonies indicate a positive test.  It was due to hydrolysis of esculin to aesculetin 
which then reacts with ferric ions to form black colonies.  
Heat tolerance test14,37,65,70:  
 Enterococcal isolates were tested for heat tolerance along with the control 
strains. After inoculating the isolates into BHI broth, those isolates were incubated 
at 60ºC for 30 minutes in a water bath. From the BHI broth subcultures were done 
on both blood agar and MacConkey agar prior to incubation and at intervals         of 
10 min, 20min and 30 minutes after incubation. Positive control used was ATCC 
E.faecalis 29212. Before reading other isolates, growth of the positive control was 
checked. The positive control strain has showed growth before and after heating the 
broth at 60ºC for 30 minutes. Similarly those isolates which showed growth before 
and after 30min of incubation at 60ºC  were  considered  as heat tolerant  
Enterococcal isolates. 
PYR Test14,37,65,66,70,71: 
 The colonies of the Enterococci isolates were inoculated in PYR broth (α - 
pyrrolidonyl β- naphthylamide) and incubated at 37
0
C for 4 hrs. A drop of PYR 
reagent which is p-dimethylamino cinnamaldehyde is added to the broth. The 
production of cherry red colour was taken as positve. Enterococci are PYR (α - 
pyrrolidonyl β- naphthylamide) Positive. 
 
Salt tolerance test14,36,37,41,65,66,70,71: 
 In brain heart infusion broth along with 6.5% Nacl, 1-2 colonies of 
Enterococci isolates were inoculated and incubated for 18-24 hrs at 37
0
C. 1 % 
Bromothymol blue (0.002%) was used as indicator. Positive test was indicated by 
the presence of turbidity in the broth & colour of the broth changed to yellow.  
 
Growth at 10° C & 45° C 14,17,37,41: 
 In brain heart infusion broth, 1-2 colonies of Enterococci isolates were 
inoculated and incubated for 18-24 at 10° C & 45° C. After incubation the tubes 
were examined for growth by rotating them in front of an incandescent lamp. 
 
Growth at pH 9.6 14,17,36,41: 
 Examined for growth at pH 9.6. All pH measurements were conducted with 
a pH meter 
Litmus Milk Decolorisation test17,41 
A heavy inoculam of the test organisim taken in a tube containing litmus 
milk and incubating it at 35-37
o
C for 4 hours. A production of white or pale yellow 
colour is taken as positive and No change or pink colour is taken as negative.  
Salt tolerant, Bile esculin agar positive isolates, which were able to grow on 
MacConkey agar and at temperatures of > 45ºC, at 10& 45ºC grown at pH 9.6 were 
identified as Enterococci and selected for further speciation6,10.  
SPECIATION OF ENTEROCOCCI  
 Enterococcal strains were further identified to the species level by using 
conventional tests designed by Facklam and Collins36. 
Sugar fermentation  
 Each strain of Enterococci were tested for its ability to ferment 
sugar16,17,33,36,37,41. 1% sugars Mannitol, Sorbitol, Sucrose, Arabinose, Raffinose, 
Sorbose, Lactose are added in Brain heart infusion broth with indicator 
bromothymol blue (0.002%). To each sugar tubes 1-2 drops 18-24 hrs old broth 
culture of enterococci are inoculated with the help of Pasteur pipette and incubated 
for 18-24 hrs at 37
0
C. It’s observed daily and kept for a period of 7 days.  
Fermentation is indicated by the colour change from blue to yellow 
26 
Arginine hydrolysis36,65,70:  
 It was tested by inoculating the Enterococci isolates into a tube of Moeller’s 
decarboxylase broth containing arginine and a control tube (without arginine). It 
was overlaid with sterile liquid paraffin and incubated at 37ºC for seven days. 
Anaerobic enviroment will be provided by overlaying liquid paraffin. Initially tube 
changed to yellow in colour and if arginine is dihydrolysed (positive test) the tube 
with arginine reverts back to the original purple colour due to alkalinization, 
Negative test is indicated by persistant yellow color. 
Positive control  : Enterococcus faecalis ATCC 29212 (purple colour)  
Negative control :  Klebsiella Pneumoniae (yellow colour)  
Pyruvate fermentation17,36 : 
Enterococci species first grown in brain heart infusion broth from which       
1 – 2 drops  was then inoculated into pyruvate broth and incubated at 37°C for     
18-24 hrs.  Bromothymol blue (0.002%) is used as indicator.   Positive test was 
indicated by the colour change from blue to yellow indicating production of acid 
due to pyruvate fermentation.  
Motility36,65,70: 
 The brain heart infusion broth culture of Enterococci are observed for 
motility by hanging drop preparation (E.casseliflavus and E.gallinarum are motile) 
 
Pigment Production36,65,70: 
 Enterococci species is streaked on Tryptose soya agar and incubated at 37 
degrees for 24 -48 hrs to look for yellow pigment production70. A cotton swab was 
used to pick up the colonies and was examined for yellow colour formation. 
(E.casseliflavus & E.munditi) produce pigment 
 
The additional tests performed were production of black coloured colonies 
on 0.04% tellurite agar, which is a feature of E.faecalis4,17,66,70,72. 
 
Characteristics of E.faecalis and E.faecium 
CHARACTERISTICS E.faecalis E.faecium 
Gram stain Gram positive cocci 
occurring  
in pairs and short chains 
Gram positive cocci 
occurring  
in pairs and short chains 
Catalase Negative Negative 
Motility Non motile Non motile 
Blood agar ( 5% SBA ) α hemolytic or non 
hemolytic 
α hemolytic or non 
hemolytic 
MacConkey agar 
  
Magenta coloured 
colonies 
Magenta coloured colonies 
CHARACTERISTICS E.faecalis E.faecium 
Bile esculin agar hydrolyses esculin and 
causes blackening of 
the medium. 
hydrolyses esculin and 
causes blackening of the 
medium. 
Heat tolerance Survived at a 
temperature of 60ºc for 
30 minutes. 
Survived at a temperature 
of 60ºc for 30 minutes. 
Salt tolerance  Survived in 6.5%NaCl Survived in 6.5%NaCl 
Pigment production  No Pigment production. No Pigment production. 
Arginine dihydrolysis Arginine  hydrolysed, 
produces Deep purple 
colour 
Arginine  hydrolysed,  
produces Deep purple 
colour 
0.04% tellurite agar Black coloured colonies 
produced. 
- 
Carbohydrate 
utilization 
(1%)  
Pyruvate and Sorbitol – 
Fermented 
Arabinose,Sorbose- Not 
Fermented 
Arabinose - fermented,  
Sorbose &Pyruvate –  
not fermented. 
 
E.raffinosus, E.avium, E.durans, E.hirae were differentiated based on the 
following characteristics 
 
Enterococcal 
species 
Arginine 
dihydrolysis 
Fermentation of sugars 
E.raffinosus 
Group I. 
Not 
hydrolysed 
Mannitol, Raffinose, Arabinose, Sorbose 
fermented 
E.avium 
Group I 
Not 
hydrolysed 
Mannitol , Arabinose, Sorbose fermented, 
Raffinose not fermented 
E.durans 
Group III 
Hydrolysed 
Raffinose, Sucrose & Pyruvate not 
fermented. 
E.hirae 
GroupIII. 
Hydrolysed 
Raffinose & Sucrose Fermented 
Pyruvate not fermented 
 
Speciation of Enterococci 
Species Mannitol Arabinose Raffinose Sorbitol Sucrose Pyruvate Arginine 
E.faecalis + - - - + + + 
E.faecium + + V - + - + 
E.raffinosus + + + + + + - 
E .avium + + - + + + - 
E.durans - - - - - - + 
E.hirae - - + - + - + 
 
DETECTION OF VIRULENCE FACTORS OF ENTEROCOCCI: 
Haemolysin6,67,73,74:  
 The hemolysin production by Enterococci was tested by the plate hemolysis 
test.  Enterococci was inoculated onto 5% sheep blood agar and incubated at 
overnight 35 degree celcius67,73,74.  Haemolysin production is indicated by  a zone 
of complete lysis of the RBCS  around the colony with clearing of the  surrounding  
medium74.  
Gelatinase Production6,67,73,74:  
 Gelatinase production was tested with gelatin agar. Enterococci was 
inoculated onto the plate and was incubated at 37 degree Celsius for 24 hours.   A 
turbid halo or a zone of clearing around   the colonies was considered Positive for 
Gelatinase  production 6,73,74. 
 
 
Biofilm73,74,75:  
 The organisms were isolated from fresh culture plates and were inoculated 
into Brain Heart Infusion Broth added with 2% sucrose and incubated for 24 hours 
at 370 celsius. Broth was diluted to 1: 100 with fresh medium,. A sterile polystyrene 
96 wells, flat bottom culture plate was taken and to which 200 microlitres of the 
diluted cultures were inoculated 73,74. Only medium without any culture was used as 
control in order to check the sterility and the non specific binding of the media. At 
370 celsius for 24 hours the tissue culture plate was incubate.  After the incubation 
period, the contents of each well were removed by tapping the plates. To remove 
the free floating planktonic bacteria, wells were washed for 4 times using 0.2 ml of 
phosphate buffer saline. Following which fixation was done with 2% sodium 
acetate to fix the biofilms formed within the plate.  Again it was stained for one 
minute with 0.1% crystal violet. Thorough washing with deionised water is 
important to remove excess stain and plate was kept for drying. If the organisms 
were adherent, they usually form biofilm on all the sides of the well and with 
crystal violet were uniformly stained. At a wavelength of 570 nm using micro 
ELISA auto reader, Optical density (OD) of stained bacteria were detected. OD 
values were considered as index of bacteria adhering to surface and the biofilm 
formation. Usually this procedure was done in triplicate, data averaged and the 
standard deviation was calculated. Usually Media control well’s mean OD value 
was subtracted from all the test values. Those OD values >0.2, 0.081-0.2,<0.081 
were considered as High, Moderate, Low biofilm producers respectively74. 
 
ANTIBIOTIC SUSCEPTIBILITY TESTING 
Using Kirby Bauer disk diffusion method on Mueller Hinton agar, Antibiotic 
susceptibility testing was performed. Interpretation of the results were made by 
measuring the zone size of inhibition according to CLSI 2015(M100-S25) 
guidelines.  Enterococcus faecalis (ATCC 29212),   was used as quality control 
strains76,77. 
TURBIDITY STANDARD FOR INOCULAM PREPARATION 63,78,79 
For an antibiotic susceptibility test, inoculum density  was standardized by a 
Barium sulfate(BaSO4) turbidity standard, It should be equal to 0.5 McFarland 
standard or its optical equivalent (e.g., latex particle suspension). 
Inoculum preparation  
Approximately 3-5 morphologically similar colonies must be taken and in a 
sterile test tube it was mixed with about 4-5 ml of a suitable broth medium. The 
broth culture is then incubated at 35˚C till it attains 0.5 McFarland standard 
turbidity. This suspension approximately represent 150 million organisms/ml. 
Method of inoculation of test plates 
The turbidity of the test medium was adjusted, it was inoculated within 15 
minutes into the plates. A sterile cotton swab was taken and immersed into the 
suspension. To get rid of the excess inoculum from the swab it was pressed by the 
sides of the tube. A dried Mueller Hinton agar plate was taken and the swab was 
then streaked onto it. This procedure of streaking was repeated for 2-3 times by 
rotating the plate at 60˚ so that the uniform distribution of the inoculum over the 
plate was possible. Finally, it was swabbed around the rim of the plate. Within 15 
minutes, the antibiotic discs were dispensed onto the plate. It should be pressed 
firmly to achieve complete contact of the discs with the surface of the agar. It was 
ensured that the discs were kept at 24mm from center to center. After dispensing 
the drugs, within 15 minutes the plate was kept in the incubator in inverted position.  
The plate was then examined after overnight (16-18 hrs) incubation. If the inoculum 
was good, then a confluent lawn of growth will be seen and the zone of inhibition 
will also be seen as uniformly circular. The diameter of the inhibition zone were 
then calculated with the help of rulers or sliding calipers.  The zone of inhibition of 
the bacterial growth around each disc is measured under reflected light except for 
Vancomycin which should be read through transmitted light. According to the CLSI 
guidelines 2015, the interpretation were made as susceptible, intermediate and 
resistant76. 
The antibiotics tested were as follows 
 Penicillin 10U, Ampicillin (10 μg), Erythromycin (15μg),   Doxycycline 
(30μg), Ciprofloxacin (5μg), Levofloxacin (5μg), High level gentamicin (120μg), 
High level streptomycin (300μg), Nitrofurantoin (300μg), Vancomycin (30μg),  
Teicoplanin (30μg), Linezolid 
 Nitrofurantoin used only in Urinary isolates 80,81. Erythromycin used only in 
other than urinary isolates81.For VRE isolates (Both E.faecalis & E.faecium) - 
Linezolid (30μg), Tigecycline (15 μg)3. For VRE (only E.faecium) – Quinpristin / 
Dalfopristin (15μg) 3,27.  
SCREENING TESTS FOR HIGH LEVEL AMINOGLYCOSIDE 
RESISTANCE (HLAR)67,68,70,81,82,83: 
 
 The Enterococci isolates were screened for High level Aminoglycoside 
resistance by using the antibiotic discs – High level streptomycin (HLS) 300μg and 
High level gentamicin (HLG) 120μg67.  On Mueller Hinton agar using McFarland 
0.5 turbidity standard of bacterial suspension,  streaking was made and  discs were 
kept  by standard disc diffusion method as described above and incubated  
overnight at 37ºC. As per CLSI standards the results were interpreted susceptible 
10mm, inconclusive-7-9mm, resistant – 6mm67,76.    
 
DETECTION OF VANCOMYCIN RESISTANCE 
 
VANCOMYCIN SCREEN AGAR 4,67,68 ,84,85,86: 
  
 Presumptive identification of  resistance  to can be done by using 
Vancomycin screen agar (ie) brain heart infusion (BHI) agar added with 6 μg /ml 
vancomycin10B,67,85. 10μl each of 0.5 McFarland suspension of the isolate, along 
with negative and positive  control strains, were spot  inoculated over  the surface  
of agar and aerobically incubated at 35±2ºC for 24hrs. Presumptive resistance to 
vancomycin was indicated by the growth of one or more colonies. It should be 
followed by by determination of the Minimum inhibitory concentration (MIC) for 
vancomycin which is confirmatory67,68,87.  
 
VANCOMYCIN E TEST6,65,68,84,88 
By Kirby bauer disc diffusion method, those Enterococci that were 
intermediate sensitive or resistant to Vancomycin were confirmed by determination 
of their Minimum inhibitory concentration (MIC) by E- test or Epsilometric test  
 Method: A lawn culture of Enterococci of 0.5 Mcfarland standards was 
done on 5% Mueller Hinton agar. By using sterile forceps, MIC (E) strip was taken 
and applied on to the plate in such a way that its MIC scale facing up and higher 
concentration facing the edge of the plate. Incubate it 18 -24 hrs at 37 degrees and 
examine it.  Results were interpreted according to CLSI guidelines 2015 by the 
zone of inhibition in form of ellipse76.  
TEICOPLANIN E TEST88  
  On 5% Mueller Hinton agar, a lawn culture of Enterococci of 0.5 Mcfarland 
standards was done. MIC (E) strip was applied on to the plate by using sterile 
forceps. At 37 degrees it was Incubated for 18 -24.  Results were interpreted 
according to CLSI 2015 guidelines. 
Antibiotics Kept 
By E-strip 
Method 
MIC Interpretive Criteria (μg/mL) 
Sensitive Intermediate Resistant 
Vancomycin ≤4 8-16 ≥32 
Teicoplanin ≤8 16 ≥32 
 
 
 
 
MIC FOR VANCOMYCIN BY AGAR DILUTION METHOD70 
 Determination of MIC of Vancomycin for Enterococcal isolates which grew 
on Vancomycin agar screen was done by Agar dilution method 67,87,89. 
Procedure Included were:  
1) Dilution of Antibiotics. 
 2) Inoculum Preparation.  
 
1) Dilution of Antibiotics: 
a) Range of dilution:  
 
 It was made according to CLSI guidelines, took two dilutions above and 
below the range decided. For Vancomycin to Enterococci (1- 128 µg/ml). Sensitive 
≤ 4 µg/ml, Intermediate 8-16µg/ml, resistant ≥ 32µg/ml. 18 ml of Mueller Hinton 
agar with 2ml of antibiotic was taken. 1 ml should contain antibiotic for 10ml of 
media highest concentration, so needed is 128 µg/ml. Thus for 10ml it is 1280 
µg/10ml. 
 
 b) Calculation of Stock Solution 
 Volume (ml) = [wt of antibiotic (mg) * Potency (µg / mg) / concentration 
(µg/ ml)] For 20ml, stock solution, 20 =[ Xmg * 1000 / 1280],  Hence X=25.6 mg.  
So, 25.6 mg of vancomycin was dissolved in 20ml of distilled water. Stock solution 
could be preserved for a week by storing it at 8°C and pure drug can be kept in deep 
freezer at - 20° C for a week. 
  
c) Serial double dilution done with 2ml volume.  
 
In this study dilution range (32µg/ml→ 0.25µg/ml). Then Mueller Hinton 
agar was cooled to 45° to 50° C after autoclaving (121 C 15lb for 15 minutes). 
Mueller Hinton agar 18ml was added for every dilution, mixed and poured in 
respective Petri dishes.  All the plates along were incubated for 18hrs at 35° C.   For 
sterility check a control plate was also incubated along with the test plates.  
 
2) Preparation of inoculums:  
 
To 3ml of peptone water, 5-6 colonies were inoculated and then it was 
incubated for 3- 8 hours at 37°C to adjust the turbidity to 0.5 Mc Farland standards 
(1.5x10 CFU/ml). Later 1:10, 1:100 dilutions to get 10 CFU/ml, finally 10µl of 4 
diluted growth carries 10 CFU per spot inoculation to the respective plates. All test 
strains were inoculated with susceptible and resistant strains into various 
concentration of agar plates and drug free (control) plate. Incubate at 37 C for 18-20 
hours.  
 
Reporting  
 Confirm all the test strains along with control strains have grown on control 
plate (plate without the drug). Confirm whether the controls were within the normal 
range. If the above said things were confirmed then only reporting to be done 
further and MIC is validated. Minimum inhibitory concentration of the drug was 
taken as the lowest concentration of drug that could inhibit the growth of the 
organism.  
Enterococci MIC for Vancomycin interpreted as follows: 
≤4μg/ml-Sensitive, 8-16μg/ml- Intermediately Resistant and ≥32μg/ml - Resistant 
 
MOLECULAR METHOD FOR THE DETECTION OF VRE4,86,89: 
 Polymerase chain reaction (PCR) assay was performed by the for the 
detection of genes responsible for Vancomycin resistance in Enterococci especially 
in E.faecalis and  E.faecium. The DNA was extracted from the Enterococci isolates 
by using  Pure Fast Bacterial Genomic DNA Mini Spin Prep Kit and subjected to 
PCR and using  gel electrophoresis gene product were viewed. 
 
Master Mix 2X - Constituents  
1. Taq DNA Polymerase  -  2Units  
2. Taq reaction buffer  - 10X    
3. Magnesium Chloride. - 2mM 
4. 10mMdNTPs mix   -  1μl. 
5. Polymerase Chain Reaction additives. 
 
For Gel Electrophoresis  
1. Agarose, 2. 50XTAE buffer, 3. 6Xgel loading buffer, 4. Ethidium 
bromide  
Extraction of DNA from the Enterococcal isolates: 
1. 1.5ml of overnight culture taken & centrifuged at 12000 rpm at 4º C for 
5min. 
2. To the pellet 180μl of Lysozyme digestion buffer was added 
3. To this 20μl of Lysozyme was added and incubated for 10 min at 37 ºC. 
4. Then 200μl of Lysis buffer was added. 
5. Then20_l of proteinase K was added mixed well, incubated at 56ºC for 15 
min in water bath 
6. To this 200μl of Isopropanol added & mixed well by inverting several 
times.Whole sample was transferred to spin column using pipette & 
centrifuged for1min at 10,000rpm. 
7. 500μl of wash buffer added to the spin column and centrifuged for 30 
seconds & the flow-through was discarded, the spin column is placed back 
in collection tube. 
8. Washing repeated twice using wash buffer II. 
9. The flow- through is discarded mini spin centrifuged for 1 min to remove 
residual ethanol. 
10. The spin column is placed in a fresh centrifuge tube and 50μl of pre 
warmed Elution buffer was added to the spin column, incubated for 2 min 
at room temperature, centrifuged for 1min. 
11. Then the spin column is discarded DNA present in the centrifuge tube is 
stored at at -20º C. 
 
5μl of this elute was used for PCR. 
The vanA Primers designed by as follows. 
Forward Primer: 5’ -TGCGCGGAATGGGAAAACGACA-3’ 
Reverse Primer: 5’ -CAGCCCGAAACAGCCTGCTCAA-3’ 
The PCR Product size is 473bp representing van A gene. 
The vanB primers designed by as follows. 
Forward Primer: 5’ - TCTTTGTGAAGCCGGCACGGTC -3’ 
Reverse Primer: 5’ -  AGCCGACCTCACAGCCCGAAAT -3’ 
 PCR Product size is 147bp representing van B gene. 
An optimal negative control was employed using 1 μl molecular grade water. 
PCR amplification: 
 The PCR reactant mixture for each sample is prepared by adding 20_l of 
PCR Master Mix, 2_l of Van A Gene specific Primer mix , 5_l of Purified DNA of 
each sample and 3_l of Nuclease free water to a total final volume of 30_l.PCR 
amplification was performed in thermal cycler (MyGenie, Bioneer,South Korea) 
using the following thermal profile which consists of one cycle of initial 
denaturation at 95ºC for 4min followed by 35 cycle of denaturation at 95ºC for 
30sec, primer annealing at 62ºC for 30sec, extension at 72ºC – 30sec and one cycle 
of Final extension at 72ºC for 5min. 
 
Analysis of PCR product was done by agarose gel electrophoresis. 
About 1.5% of agarose gel was prepared by mixing 0.75 grams of agarose 
powder in 50 ml of electrophoresis buffer and heated in a microwave oven till 
agarose is uniformly dissolved. After cooling to 56ºC, 5μl of Ethidium bromide was 
added using gloved hands. Ethidium bromide is carcinogenic and hence should be 
handled with gloved hands and the tip is discarded into the black bin. After cooling 
the solution, it is poured into a gel casting tray containing comb and allowed to 
solidify. After hardening, the gel is placed in the electrophoresis tank. The 
electrophoresis buffer provided in the kit is diluted ten times and is poured into the 
tank till the gel is completely immersed, then the comb was carefully removed. 
Then the electrical leads were connected to the electrophoresis tank. About 15μl of 
loading buffer containing the PCR product and the tracking dye is loaded into each 
well using micropipette. About 10μl of 100 bp DNA ladder was loaded into the first 
well followed by 15μl of the sample in the other wells. A constant current of 100 
volts was applied and the gel is allowed to run till the tracking dye reaches three 
fourth of the gel. Then the gel tray is removed from the tank. Then the gel is 
removed from the tray and placed in the UV transilluminator for observation of 
bands of 473 bp and 147bp size for van A and    van B primer respectively. 
 
STATISTICAL ANALYSIS   
 The outcome of the study was observed, recorded and analysed. The data 
which were analysed were presented in the form of statistical tables, histograms and 
pie charts in appropriate places wherever necessary. All the data were documented 
and studied in detail. P values were calculated by Chi –Square test to compare the 
proportion between categorical variables. If expected cell frequency is less than five 
in more than 20% of cells then Fisher’s exact Chi –Square test is applied. SPSS 
(Stastical package for the social science) version 22.0 is used to analyse the data. 
Significance level is fixed as 5% (α=0.005).The documented data were further in 
detail compared and discussed and with studies those having similar data & results 
which were published in reputed scientific journals. 
RESULTS 
 This study was carried out in the department of Microbiology during the 12 
month period from January 2015 to December 2015.  The results were analyzed as 
follows.  A total of about 240 Enterococcal isolates were recovered from the above 
samples, of which majority were from 131 urine specimens, 60 from pus 
specimens, 31 from blood specimens,  18 from High Vaginal swabs. 
 
Table-1 AGEWISE DISTRIBUTION OF PATIENTS WITH ENTEROCOCCAL 
ISOLATES (n=240) 
AGE GROUP (IN YEARS) 
NO. OF PAIENTS WITH  
ENTEROCOCCAL ISOLATES 
0-1 9(3.75%) 
1-15 18(7.50%) 
16-30 61(25.42%) 
31-45 56(23.33%) 
46-60 62(25.83%) 
61-75 29(12.08%) 
>75 5(2.08%) 
Total 240(100%) 
 
 Among the isolates 25.83% are from 46-60 years age group followed by 
25.42% in 16-30years ,  23.33% in 31-45 years and 12.08% in 61-75 years ,which 
showed significance statistical value p<0.001. Out of the total 240 Enterococci 
isolated, majority were isolated from adult patients 215 (89.58%), however around 
25(11.42% ) of isolates from pediatric patients. 
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 TABLE 2. SEXWISE DISTRIBUTION OF PATIENTS WITH 
ENTEROCOCCAL ISOLATES (n=240) 
 
SEX 
NO. OF PAIENTS WITH  
ENTEROCOCCAL ISOLATES 
Male 129(53.75%) 
Female 111(46.25%) 
Total 240 
 
Among 240 Enterococcal Isolates, Male: Female ratio is 1.17:1.  
Males form 53.75% of the isolates and female 46.25% of the isolates 
 
TABLE-3 DISTRIBUTION OF ENTEROCOCCAL ISOLATES (n=240) 
ENTEROCOCCAL SPECIES NO. OF ORGANISMS 
E.faecalis 150(62.50%) 
E.faecium 78(32.50%) 
E.raffinosus 6(2.50%) 
E.avium 3(1.25%) 
E.durans 2(0.83%) 
E.hirae 1(0.42%) 
TOTAL 240 
 
 Out of 240 Enterococcal isolates, E.faecalis is the predominant species 
150(62.50%), followed by E.faecium 78(32.50%) and rest contributes to  5%, which 
is significant as P value showed <0.001 
 
  
TABLE-4   DISTRIBUTION OF ENTEROCOCCAL ISOLATES AMONG 
VARIOUS SPECIMENS (n=240) 
ENTEROCOCCAL 
SPECIES  
URINE 
PUS /  
WOUND SWAB 
BLOOD 
HIGH 
VAGINAL 
SWAB 
TOTAL NO. OF 
ORGANISMS 
E.faecalis (n=150) 87(66.41%) 31(51.67%) 18(58.06) 14(77.78%) 150(62.50%) 
E.faecium (n=78) 36(27.48%) 26(43.33%) 12(38.71%) 4(22.22%) 78(32.50%) 
E.raffinosus (n=6) 4(3.05%) 1(1.67%) 1(3.23%) - 6(2.50%) 
E.avium (n=3) 2(1.53%) 1(1.67%) - - 3(1.25%) 
E.durans (n=2) 1(0.76%) 1(1.67%) - - 2(0.83%) 
E.hirae (n=1) 1(0.76%) - - - 1(0.42%) 
TOTAL 131 (54.58%) 60 (25%) 31 (12.92%) 18 (7.50%) 240(100%) 
 
The isolates were from Urine 131(54.58%), Pus 60(25%), Blood 31(12.92%), and 
High vaginal Swab 18 (7.50%) 
 
TABLE-5   DISTRIBUTION OF ENTEROCOCCAL ISOLATES (n=240) 
ENTEROCOCCAL 
SPECIES 
ICU NON ICU 
 (OTHER WARDS) 
OPD 
E.faecalis 14(5.83%) 120(50%) 16(6.67%) 
E.faecium 16(6.67%) 52(21.67%) 10(4.17%) 
E.raffinosus 1(0.42%) 5(2.08%) - 
E.avium - 1(0.42%%) 2(0.83%) 
E.durans - 2(0.83%) - 
E.hirae - - 1(0.42%) 
TOTAL 31 (12.92%) 180(75%) 29(12.08%) 
  
In ICU set up E.faecium is the predominant species isolated followed by E.faecalis, 
E.raffinosus. Isolates were more from Non ICU (75%) followed by ICU (12.92%), 
and OPD (12.08%), which is statistically significant as P value showed <0.001. 
 
TABLE-6 WARD WISE DISTRIBUTION OF ENTEROCOCCAL ISOLATES 
IN VARIOUS CLINICAL SPECIMENS (n=240) 
 
NAME OF 
THE WARD 
URINE PUS BLOOD 
HIGH VAGINAL 
SWAB 
TOTAL 
ISOLATES 
ICU 3 11 17 - 31(12.92%) 
Medicine 28 
 
9 - 37(15.42%) 
Surgery 55 23 1 - 79(32.92%) 
Pediatrics 8 2 1 - 11(4.58%) 
OG 11 1 1 18 31(12.92%) 
Burns - 20 2 - 22(9.17%) 
OPD 26 3 - - 29(12.08%) 
TOTAL 131 60 31 18 240(100%) 
 
32.92% isolates were from Surgical ward followed by 15.42% from Medical Ward, 
12.08% isolates were from OPD, which is statistically significant as P<0.001. 
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TABLE -7 DISTRIBUTION OF ENTEROCOCCAL ISOLATES WITH 
ASSOCIATED RISK FACTORS / CO MORBID CONDITIONS (n=240) 
 
ENTEROCOCCAL 
 SPECIES  
URINARY 
CATHETE
RISATION 
BURNS DIABETES  
POST 
OPERATIVE 
WOUND 
INFECTION 
SEPTICEMIA 
E.faecalis 18 18 7 6 7 
E.faecium 12 14 15 6 3 
E.raffinosus 1 - - - 
 
E.avium - - 1 - 
 
E.durans - 1 - - 
 
E.hirae - - - - 
 
TOTAL 31(12.92%) 33(13.7%) 23(9.58%) 12(5%) 10(4.17%) 
 
 Enterococci were isolated more from burns wound (13.7%) followed by 
Urinary catheterization (12.92%), Diabetes (9.58%), Post operative infection (5%), 
Septicemia (4.17%). 
TABLE - 8   CORRELATION BETWEEN CATHETERISATION AND 
ENTEROCOCCAL INFECTION (UTI) (n=131) 
 
ENTEROCOCCAL 
SPECIES 
CATHETERISED 
URINE 
NON CATHETERISED URINE 
E.faecalis 19(14.05%) 68(51.91%) 
E.faecium 8(6.11%) 28(21.37%) 
E.raffinosus 1(0.76%) 3(2.29%) 
E.avium - 2(1.53%) 
E.durans - 1(0.76%) 
E.hirae - 1(0.76%) 
TOTAL 28(21.37%) 103(78.63%) 
 
Out of the 131 Urine samples 28(21.37%) were from catheterised patients.  
From the catheterised patients 19 were E.faecalis, 8 were E.faecium  
& 1 was E.raffinosus. 
 
TABLE-9 IDENTIFICATION OF ENTEROCOCCUS SPECIES (n=240) 
 
Biochemical 
Test 
E.faecalis 
(n=150) 
E.faecium 
(n=78) 
E.raffinosus 
(n=6) 
E.avium 
(n=3) 
E.durans 
(n=2) 
E.hirae 
(n=1) 
Glucose 150(100%) 78(100%) 6(100%) 3(100%) 2(100%) 1(100%) 
Mannitol 150(100%) 75(96.15%) 6(100%) 3(100%) - - 
Arabinose - 78(100%) 6(100%) 3(100%) - - 
Raffinose - 28(35.89%) 6(100%) - - 1(100%) 
Sorbitol 140(100%) 44(56.41) 6(100%) 3(100%) - - 
Sucrose 150(100%) 78(100%) 6(100%) 3(100%) - 1(100%) 
Lactose 144(96%) 78(100%) 6(100%) 
2(66.67%
) 
2(100%) - 
Pyruvate 
Utilization 
150(100%) - 5(80%) 3(100%) - - 
Arginine 
Decarboxylat
ion 
150(100%) 78(100%) - - 2(100%) 1(100%) 
Tellurite 
Reduction 
150(100%) - - - - - 
 
 Identification of Enterococci to the species level was readily achieved by 
using the battery of biochemical tests suggested by Facklam and Collins. 
 
 
  
TABLE-10 PRODUCTION OF VIRULENCE FACTORS AMONG 
ENTEROCOCCAL ISOLATES (n=240) 
 
ENTEROCOCCAL 
SPECIES  
HEMOLYSIN GELATINASE BIOFILM 
E.faecalis (n=150) 30(20%) 42(28%) 78(52%) 
E.faecium (n=78) 14(18%) 20(25.64%) 33(42.30%) 
TOTAL 44(18.33%) 62(25.83%) 114(47.5%) 
 
 Hemolysin, Gelatinase, Biofilm were produced by E.faecalis & E.faecium. 
E.faecalis 30(20%) showed more production of Hemolysin than E.faecium 
14(18%). Gelatinase was produced by E.faecalis 42(28%), E.faecium 78(52%). 
Biofilm was produced by E.faecalis 78(52%), E.faecium 33(42.30%).  
 
TABLE-11 PRODUCTION OF VIRULENCE FACTORS AMONG 
ENTEROCOCCAL ISOLATES IN PATIENTS WITH ASSOCIATED   RISK 
FACTORS / CO MORBID CONDITIONS (n=240) 
 
RISK FACTORS / CO 
MORBID CONDITIONS 
HEMOLYSIN GELATINASE BIOFILM 
Urinary tract Infection 
(n=131) 
27(20.61%) 31(23.66%) 65(49.62%) 
Burns (n=33) 6(18.18%) 11(33.33%) 20(60.61%) 
Diabetes mellitus (n=23) 2(8.70%) 8(34.78%) 12(52.17%) 
Post operative Wound 
Infection (n=12) 
4(33.33%) 5(41.67%) 8(66.67%) 
Septicemia (n=10) 3(30%) 4(30%) 6(60%) 
Others (n=31) 2(6.45%) 3(12.90%) 3(9.68%) 
TOTAL 44(18.33%) 62(25.83%) 114(47.5%) 
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 Virulence factors were more produced in Post operative wound infection 
followed by burns wound infection, septicemia, diabetes, urinary tract infections. 
Hemolysin, Gelatinase, Biofilm were more produced in Post operative wound 
infection. 
TABLE -12 ANTIBIOTIC SUSCEPTIBILITY PATTERN OF E.FAECALIS 
BY KIRBY BAUER DISC DIFFUSION METHOD (n=150) 
ANTIBIOTICS Dosage Units 
E.faecalis 
Sensitive Resistant 
Penicillin G   10U 36(24%) 114(76%) 
Ampicillin  10 μg 69(46%) 81(54%) 
Erythromycin 15 μg 25*(39.68%) 38*(60.32%) 
Doxycycline  30 μg 93(62%) 57(38%) 
Ciprofloxacin 5 μg 66(44%) 84(56%) 
Levofloxacin 5 μg 88(58.67%) 62(41.33%) 
Nitrofurantoin 300 μg 114(76%) 36(24%) 
High level gentamicin 120 μg 67(44.67%) 83(55.33%) 
High level Streptomycin 300 μg 49(32.67%) 101(67.33%) 
Vancomycin 30 μg 148(98.67%) 2(1.33%) 
Teicoplanin 30 μg 149(99.33%) 1(0.67%) 
Linezolid 30 μg 150(100%) - 
 
 Erythromycin is not reported in Urinary Isolates (CLSI 2015) 
Among E.faecalis, Linezolid showed 100% susceptibility, followed by Teicoplanin 
(99.33%) and Vancomycin (98.67%), least susceptibility was with Pencillin G 
(24%), followed by  High level Streptomycin (32.67%%), Erythromycin (39.68%). 
TABLE – 13. ANTIBIOTIC SUSCEPTIBILITY PATTERN OF E.FAECIUM 
BY KIRBY BAUER DISC DIFFUSION METHOD (n=78) 
 
ANTIBIOTICS Dosage Units 
E.faecium 
Sensitive Resistant 
Penicillin G   10U 14(17.95%) 64(82.05%) 
Ampicillin  10 μg 32(41.03%) 46(58.97%) 
Erythromycin 15 μg 12(28.57%) 42(71.43%) 
Doxycycline  30 μg 45(57.69%) 33(42.31%) 
Ciprofloxacin 5 μg 26(33.33%) 52(66.67%) 
Levofloxacin 5 μg 42(53.85%) 36(46.15%) 
Nitrofurantoin 300 μg 54(69.23%) 24(30.77%) 
High level gentamicin 120 μg 31(39.74%) 47(60.26%) 
High level Streptomycin 300 μg 26(33.33%) 52(66.67%) 
Vancomycin 30 μg 74(94.87%) 4(5.13%) 
Teicoplanin 30 μg 75(96.15%) 3(3.85%) 
Linezolid 30 μg 78(100%) - 
 
Erythromycin is not reported in Urinary Isolates (CLSI 2015) 
 E.faecium showed higher suscpetibility to Linezolid (100%) followed by 
Teicoplanin (96.15%) & Vancomycin (94.87%) It showed lower susceptibility to 
Pencillin G (17.95%), followed by Erythromycin (28.57%), High level 
Streptomycin (33.33%), Ciprofloxacin (33.33%) 
 
TABLE – 14 ANTIBIOTIC SUSCEPTIBILITY PATTERN OF REST OF 
THE ENTEROCOCCAL SPECIES BY KIRBY BAUER DISC DIFFUSION 
METHOD: 
 
ANTIBIOTICS 
Dosage 
Units 
E.raffinosus 
(n=6) 
E.avium (n=3) 
E.durans  
(n=2) 
E.hirae (n=1) 
Penicillin G   10U 2 (33.33%) 1(33.33%) - - 
Ampicillin  10 μg 3 (50%) 1(33.33%) 1(50%) 1(100%) 
Erythromycin 15 μg 2* (100%) 1*(100%) 1*(100%) - 
Doxycycline  30 μg 5 (83.33%) 2(66.67%) 2(100%) 1(100%) 
Ciprofloxacin 5 μg 3 (50%) 2(66.67%) 1(50%) - 
Levofloxacin 5 μg 2 (33.33%) 2 (66.67%) 2(100%) 1(100%) 
Nitrofurantoin 300 μg 5 (83.33%) 3 (100%) 2(100%) 1(100%) 
High level 
Gentamicin 
120 μg 3 (50%) 2 (66.67%) 2(100%) 1(100%) 
High level 
Streptomycin 
300 μg 2 (33.33%) 2 (66.67%) 1(50%) 1(100%) 
Vancomycin 30 μg 6 (100%) 3 (100%) 2(100%) 1(100%) 
Teicoplanin 30 μg 6 (100%) 3 (100%) 2(100%) 1(100%) 
Linezolid 30 μg 6 (100%) 3 (100%) 2(100%) 1(100%) 
 
 
 Erythromycin is not reported in Urinary Isolates - CLSI 2015. 
 
Vancomycin, Teicoplanin & Linezolid showed highest susceptibility to all 4 
species. Penicillin G is the least Susceptible to all 4 species 
 
 
 
 
 
TABLE - 15 HIGH LEVEL AMINOGLYCOSIDE RESISTANCE IN 
ENTEROCOCCAL ISOLATES BY KIRBY BAUER DISC DIFFUSION METHOD 
 
RESISTANCE 
PATTERN 
E.faecalis (n=150) E.faecium (n=78) 
No. of Isolates % No. of Isolates % 
HLGR Alone 40 26.67% 7 8.97% 
HLSR Alone 58 38.66% 12 15.38% 
Both HLGR & HLSR 
(HLAR) 
43 28.67% 40 51.28% 
  
High Level Aminoglycoside Resistance is among 43 isolates (28.67%) in E.faecalis and 
among 40 isolates (51.28%) in E.faecium 
 
TABLE-16   DISTRIBUTION OF VANCOMYCIN RESISTANT ENTEROCOCCI 
IN VARIOUS CLINICAL SPECIMENS (n=6) 
 
SPECIMEN 
Total No. of 
Isolates 
VANCOMYCIN RESISTANT ENTEROCOCCI 
E.faecalis E.Faecium Total 
Urine 131 1 2 3 (2.29%) 
Pus 60 1 1 2(3.33%) 
Blood 31 - 1 1(3.23%) 
TOTAL 240 2 6 6(2.5%) 
 
 Among 6 VRE isolates, 3 were from Urine, 2 from Pus & 1 from Blood 
  
TABLE -17   DISTRIBUTION OF VRE AMONG THE PATIENTS WITH 
RISK FACTORS / CO MORBID CONDITION (n=6) 
 
ENTEROCOCCAL 
SPECIES 
URINARY 
CATHETE
RISATION 
BURNS DIABETES 
POST 
OPERATIVE 
INFECTION 
SEPTI 
CEMIA 
Total Isolates 31 33 23 12 10 
VRE 1 1 1 2 1 
  
 All 6 VRE isolates were associated with any one of these risk factors 
TABLE18. PHENOTYPIC CLASSIFICATION OF VANCOMYCIN 
RESISTANT ENTEROCOCCI ISOLATES BASED ON MIC 
INTERPRETATION BY E-STRIP OF VANCOMYCIN AND 
TEICOPLANIN (n=6) 
Van phenotype E.faecalis E.faecium Total 
van A  
Vancomycin MIC    32-64 μg/ml  (R) & 
Teicoplanin MIC   >16μg/ml        (R) 
1(50%) 3(75%) 4(66.67%) 
van B  
Vancomycin MIC     >8 μg/ml    (IM/R) 
& Teicoplanin MIC    0.5-1 μg/ml   (S) 
 
1(50%) 1(25%) 2(33.33%) 
Total VRE isolates 2(33.33%) 4(66.67%) 6(100%) 
  
As per the above results, the vanA phenotype showing resistance to both 
vancomycin (64μg/ml) and teicoplanin (16 μg/ml) was observed in 4VRE isolates 
(66.67%). About 2 isolates belong to vanB (33.33%) (Phenotype with vancomycin 
MIC>8 μg/ml including the intermediate and resistant range and teicoplanin MIC in 
the susceptible range usually (0.5-1μg/ml) interpreted as per CLSI guidelines 2015. 
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 TABLE. 19     MIC VALUES FOR VANCOMYCIN FOR VANCOMYCIN 
RESISTANT ENTEROCOCCI SUSPECTED ISOLATES BY AGAR 
DILUTION METHOD (n=6) 
VRE  
SUSPECTED 
ISOLATES 
(n=9) 
VANCOMYCIN MIC VALUES IN (μg/ml) 
TOTAL SENSITIVE INTERMEDIATE RESISTANT 
<4 
μg/ml 
8 
μg/ml 
16 
μg/ml 
32 
μg/
ml 
64 
μg/
ml 
128 
μg/
ml 
256 
μg/
ml 
512 
μg/
ml 
E.faecalis - - - 1 1 - - - 3 
E.faecium - - - 1 1 1 - 1 6 
TOTAL - - - 2 2 1 - 1 9 
 MIC- Minimum inhibitory concentration 
 All the 6 VRE suspected isolates fall within the resistant range of 32-
512μg/ml, interpreted as per CLSI guidelines 2015 
TABLE - 20   THE CORRELATION OF MIC VALUES OF VANCOMYCIN 
WITH GENOTYPING FOR van A GENE (n=6) 
VRE 
ISOLATES 
NO. OF 
ISOLATES 
MIC FOR 
VANCOMYCIN 
μg/ml 
MIC FOR 
TEICOPLANIN μg/ml PRESENCE OF 
van A GENE 
32-64 
μg/ml 
>64 
μg/ml 
<8 μg/ml 16-64 μg/ml 
E.faecalis 2 2 - 1 1 1 
E.faecium 4 2 2 1 3 3 
TOTAL 6 4 2 2 4 4 
  
 Among 6 VRE isolates 4 isolates showed the presence of van A gene. 
(1E.faecalis & 3 E.faecium)   
 
TABLE-21 CHARACTERISTICS OF VANCOMYCIN RESISTANT 
ENTEROCOCCI ISOLATED IN OUR STUDY (n=6) 
VRE 
ISOLATE 
VRE 
SOURCE 
ZONE 
DIAMETER 
(mm) 
VANCO
MYCIN 
SCREEN 
AGAR 
MIC (μg/ml) 
PCR 
GENOTYPE 
V
A
N
C
O
M
Y
C
IN
 
T
E
IC
P
L
A
N
IN
 
VANCO 
MYCIN  
TEICO 
PLANIN  
E.faecalis 
Urine R S R 32 0.5 van B 
Pus R R R 64 32 van A 
E.faecium 
Urine R R R 64 32 van A 
Urine R R R 128 32 van A 
Pus R S R 32 1 van B 
Blood R R R 512 64 Van A 
R- Resistant; S -Sensitive  
Among 6 VRE isolates, 1 isolate of E.faecalis & 3 isolates of E.faecium showed 
vanA gene.  1 isolate of E.faecalis & 1 isolate of E.faecium showed van B gene. 
 
TABLE. 22- ANTIBIOTIC SUSCEPTIBILITY PATTERN OF VRE 
ISOLATES (n=6) 
VRE 
ISOLATE 
DISC DIFFUSION METHOD 
LINEZOLID 
QUINPRISTIN / 
DALFOPRISTIN 
TIGECYCLINE 
E.faecalis 2(100%) Not Applicable 2(100%) 
E.faecium 4(100%) 4(100%) 4(100%) 
Total 6(100%) 4(100%) 6(100%) 
 
 Linezolid, Tigecycline showed 100% susceptibility to all 6 VRE isolates. 
Quinipristin/Dalfopristin showed 100% susceptibility to all 4 VRE isolates 
ofEnterococcus faecium.  
  
 
  
 
  
 
  
  
  
  
  
 DISCUSSION 
Enterococcus species have become important nosocomial pathogens 
worldwide and are associated with a high mortality11. Enterococci have assumed 
great clinical importance because of their increasing resistance to various 
antimicrobial agents90.  Emergence of VRE is of concern due to the limited 
therapeutic options11.  Hence it becomes essential to detect them at the earliest and 
to treat them with appropriate therapy based on the antimicrobial susceptibility 
pattern. 
In our Study a total of about 240 Enterococcal isolates were isolated from 
Various clinical samples including urine, pus, blood, High Vaginal Swab. 
As per table-1, Enterococus species were isolated from all age groups, it 
ranged from less than one year to 80 years, the youngest was 3 days old child and 
the oldest was of 80 years age. It was more isolated from 46-60 years 62(25.83%), 
followed by 16-30 years 61(25.42%), 31-45 years 56(23.33%). In a study done by 
Modi GB et al84 where between age group of 61-75 Showing 30.40%, following 
which 46-60 years isolated 18.80%, 31-45 years isolated 15.20% which is in 
contrast to our study. But study done by D.Vijaya et al49 in which Enterococci were 
isolated more among age 21-40 years followed by 40-60 yrs, which is also in 
contrast to our study. 
As per our study in table -2, the total numbers of males were 129(53.75%) 
and females were 111(46.25%). The male to female ratio was 1.17:1. These 
findings are similar to studies done by Varun Goel et al68, A.Tripathi et al10, Modi 
G.B et al84 where Enterococci were more isolated from males and some studies 
show females were more infected than males like Maj Puneet Bhatt et al90,            
D.Vijaya et al49. 
In this study it was shown in table-3 that we   isolated E.faecalis as the 
predominant species 150(62.50%) followed by E.faecium 78(32.50%), E.raffinosus 
6(2.50%), E.avium 3(1.25%), E.durans 2(0.83%) and E.hirae 1(0.42%). E.faecalis 
is the predominant species isolated in studies done by Jahnabi Barman et al81 
(81.72%), Maj Puneet Bhatt et al90 (75%), Varun Goel et al68 (53%) but in a study 
done by Jayavarthini Manavalan et al6 they isolated E.faecium (52.38%) as the 
predominant isolate. M.sharifi-Rad et al91in their study isolated 7 Enterococcal 
species (E.faecalis, E.faecium, E.raffinosus, E.avium, E.durans, E.hirae, 
E.mundtii), also Desai et al36 isolated 7 Enterococcal species (E.faecalis, E.faecium, 
E.raffinosus, E.avium, E.hirae, E.casseliflavus, E.gallinarum) which are similar to 
the species isolated in our study. 
In our study as per table - 4, out of the 240 Enterocooal isolates the 
maximum isolates were from urine 131(54.58%) followed by pus 60 (25%), blood 
31 (12.92%) and High Vaginal Swab 18 (7.50%). In the study taken by D.Vijaya et 
al49 they isolated enterococci predominantly from urine(63%) , followed by 
pus(22%), blood(4%), high vaginal swab (3%)  . In the study taken by Varsh Gupta 
et al3  they isolated   from urine(74.67%), pus(14.67%), blood(10.67%) and the 
results are  similar to our study. In contrast were the studies done by 
Sanal.C.Fernandes et al67 where they isolated from Urine (39.3%),followed by high 
vaginal swab(35.3%), pus (15%), blood(2%) and Tripathi et al10  in their study 
isolated from pus(50.81%) followed by urine(24.46%), blood (19.22%). 
As per table -5 , a total of   31 (12.92%)  Enterococci isolates were isolated 
from intensive care units (medicine, surgery), 180 (75%) were isolated from non 
ICU, 29(12.08%) were isolated from out patient Department. This is in contrast to 
studies done by Maj Puneet Bhatt et al90 where they isolated from ICU (27%), 
Other wards (40%), OPD (33%) and Nonika Rajkumari et al92 isolated Enterococci 
from ICU (63%), Other wards (37%). A study done by Modi G.B et al84, where 
they isolated Enterococci from only 4.8% from ICU, 2.4% from Outpatient 
Department & 92.8%from other wards which is similar to our study that more 
Enterococci were isolated from other wards than ICU & OPD. 
In Table -6, we discussed about the ward wise distribution of  Enterococci  
isolates which was more from Surgical ward 79(32.92%), followed by Medical 
ward 37(15.42%),  ICU(12.92%), Obstetrics & Gynecology (12.92%), Burns  
22(9.17%). In contrast to our study findings observation were made by Modi G.B et 
al84 , where they isolated Enterococci from Medical ward (38%), followed by 
Surgical ward(27.6%), Pediatric ward (14.40%), Gynecology ward (12.80%). They 
isolated only 4.8% from ICU & 2.4% from Outpatient Department. 
In our study, in table-7 we observed that the risk factors were burns 
33(13.75%), urinary Catheterization 31(12.92%),  diabetes mellitus  23(9.58%), 
post operative wound Infection 12(5%), septicemia 31(12.92%). In a study done by 
A.Tripathi et al10 they observed the following risk factors : urinary catheterization 
(46.5%), diabetes mellitus (31.8%), post operative wound infection (8.6%). 
 In table – 8,   it shows correlation between Urinary catheterization and 
urinary tract infection. Enterococcal infection among catheterized patients were 
28(21.37%) and non catheterized patients were 103(78.63%).It is in contrast to 
studies done by  Sreeja et al65 and P.J. Desai et al36.  Sreeja et al65 in their study   
observed 35% of UTI in patients with urinary catheterization and P.J. Desai et al36  
in their study noted only 8.92% of UTI from catheterized patients.  
Table-9, shows the results of various biochemical tests used to differentiate 
Enterococci Isolates. Battery of 11 tests were done to identify the various species of 
Enterococci. Key tests involved in identification were acid production from 
Mannitol, sorbitol, arginine hydrolysis, pyruvate utilization. Along with key tests 
other differentiation tests also need to be done so as to not miss the correct 
identification of species. E.faecalis showed Lactose fermentation(96%), E.faecium 
showed Hippurate hydrolysis (41.02%), raffinose (35.89%),sorbitol (56.41%). 
E.raffinosus showed 80% to pyruvate utilization and E.avium showed 66.67% to 
Lactose fermentation. These results were in concordance with the study done by P.J 
Desai et al36 where they used similar battery of tests for the speciation of 
Enterococci. 
In our study as per table 10, study on virulence factors revealed production 
of hemolysin 18.33%, gelatinase 25.83% by Enterococci. This was  similar to 
studies done by Jayavarthini M et al6 which showed production of hemolysin 
18.25%, gelatinase 19.84% and PM Giridhara et al74 which showed production of 
hemolysin 16 %, gelatinase 39%.  Biofilm production in our study was 47.5%. It 
was  in contrast to PM Giridhara et al 74 32.5% and Jayavarthini M et al6 73.81%.  
As per table -11, among  co morbid conditions, virulence factors were more 
produced in post operative wound infection followed by burns wound infection , 
septicemia, diabetes, urinary tract infections. Hemolysin, Gelatinase, Biofilm were 
more produced in post operative wound infection. Biofilm was more produced in 
post operative wound infection (66.67%) followed by burns wound infection 
(60.61%) , septicemia(60%). Gelatinase was more produced in post operative 
wound infection (41.67%) followed bv diabetes (34.78%), burns wound infection 
(33.33%) , septicemia(30%). Hemolysin was more produced in post operative 
wound infection (33.33%) followed bv septicemia (30%), urinary tract infections 
(20.61%). In contrast, in a study done by P.M.Giridhara et al74 they observed that 
virulence factors were more produced from urinary tract infection followed by 
Diabetes mellitus, post operative wound infection. 
 In this study according to Table-12, Among E.faecalis, Linezolid showed 
100% susceptibility, followed by Teicoplanin (99.33%) and Vancomycin (98.67%), 
least susceptibility was with Pencillin G(24%), followed by  High level 
Streptomycin (32.67%%), Erythromycin (39.68%). Similarly Linezolid showed 
100% susceptibility in following studies Varun Goel et al68, Jayavarthini M et al6, 
Vijaya D et al49, Sreeja et al65. In contrast resistance to Linezolid was shown by 
studies done by Nonika Rajkumari et al92, Maj Puneet Bhatt et al90. In studies done 
by Sreeja et al65, Jayavarthini M et al6, Pencillin showed least susceptibility which 
is similar to findings of our study. In contrast Ciprofloxacin showed least 
susceptibility in a study done by Vijaya D et al49. 
 In this study according to Table-13, E.faecium showed higher suscpetibility 
to Linezolid (100%) followed by Teicoplanin (96.15%) & Vancomycin (94.87%) It 
showed lower susceptibility to Pencillin G (17.95%), followed by Erythromycin 
(28.57%), High level Streptomycin (33.33%), Ciprofloxacin (33.33%). This 
observation was similar to study done by Nonika Rajkumari et al92where they 
observed Pencillin followed by Erythromycin, Ciprofloxacin showing least 
susceptibility to E.faecium. Penicllin is the least susceptible in following studies 
done by Sreeja et al65, Jayavarthini M et al6, Vijaya D et al49.  Linezolid is 100 % 
Susceptible in studies done by Jayavarthini M et al6, Vijaya D et al49, Sreeja et al65, 
Nonika Rajkumari et al92 which was similar to our study. 
 In this study according to Table-14, Vancomycin, Teicoplanin & Linezolid 
showed highest susceptibility to E.raffinosus, Eavium, E.durans, E.hirae. It is 
similar to the studies done by Jahnabi Barman et al81, Agarwal.J, et al83. In contrast 
Vancomycin resistance were seen in studies for E.durans in Ghosh (Ray) Reena et 
al88, E.avium in Sanal C.Fernandes et al67.    Penicillin G is the least Susceptible to 
all 4 species is consistent with study done by Jahnabi Barman et al81. 
In this study table-15 showed high level aminoglycoside resistance among 
Enterococcal isolates by kirby bauer disc diffusion method. High Level 
Aminoglycoside Resistance was among 43(28.67%) in E.faecalis and among 
40(51.28%) in E.faecium. High level Gentamicin resistance alone was shown 
among 40(26.67%) in E.faecalis and 7(8.97%) in E.faecium.  Only High level 
Streptomycin resistance alone was shown among 48(32%) in E.faecalis and 
12(15.38%) in E.faecium. In our study among E. faecalis and E. faecium isolates 
resistant pattern was more to streptomycin than gentamicin, which is in contrast to 
study done by K.Suresh et al80. 
In table 16, totally 6 Vancomycin resistant Enterococci were isolated. 
Among 6 Vancomycin resistant Enterococci, 3 were from urine (1E.faecalis & 
2E.faecium), 2 were from pus (1E.faecalis & 1E.faecium), 1 was from blood 
(1E.faecium). Thus a total of about 6 (2.5%) of both E.faecium and E.faecalis VRE 
isolates have been identified in our study. Agarwal.J, et al83have reported a VRE 
isolation rate of 4.65% in E.faecalis in their study. Ghoshal U et al89 from Lucknow 
have reported a 1.4% VRE isolation (all were E.faecium) in their study which is 
lower than our study. Similarly Purva Mathur et al86 isolated 1% VRE, Gupta et al93 
isolated 2% VRE.  Similar to our study VRE isolates from urine, blood & pus were 
isolated in the study done by Kamarkar et al66.  
In our study table -17 we discussed about the   distribution of Vancomycin 
resistant Enterococci among the patients with risk factors or co morbid condition. 
Among 6 Vancomycin resistant Enterococci, 2 were from Post operative infection 
followed by 1 each from Urinary tract infection, Burns wound infection, 
Septicemia, Diabetes mellitus. In contrast in a study done by A.Tripathi et al10 
where they isolated more VRE from patients with urinary catheterization followed 
by Diabetes mellitus.  
Phenotypic classification of VRE isolates based on MIC interpretation by         
Epsilometer Strip of Vancomycin and Teicoplanin was discussed in Table 18. All 
the 6 Vancomycin resistant isolates were tested for MIC of Teicoplanin and 2 
isolates showed the MIC in the susceptible range (0.5-1 μg/ml) and 4 in resistant 
range (≥32μg/ml). Based on the MIC of vancomycin and teicoplanin, 4 VRE 
isolates (4/6) (66.67%) were of vanA phenotype showing resistance to both 
Vancomycin (32-256μg/ml) and Teicoplanin (32-64 μg/ml). The remaining 2 
isolates belong to VanB phenotype (2/6) (33.67%) with Vancomycin MIC 32 μg/ml 
and Teicoplanin MIC in the susceptible range usually (0.5-1 μg/ml). The 
observations were similar to the one made by Ghosh (Ray) Reena et al88 in their 
study. Ghoshal. U et al89 where they observed Teicoplanin MIC range ≥32μg/ml in 
all their VRE isolates. 
In our study as per table 19, Minimum Inhibitory Concentration was 
determined by agar dilution method for Vancomycin for VRE suspected isolates. 
All the 6 VRE suspected isolates fall within the resistant range of 32-512μg/ml. 
This observation was in similar to studies done by Ghosh (Ray) Reena et al88, 
Agarwal.J et al83. 
In table 20, among 6 VRE isolates, High level resistance to both 
Vancomycin and Teicoplanin was shown by 3 E.faecium and 1 E,faecalis which 
belongs to  van A phenotype. Thus there is 100% concordance of phenotypic 
classification by Vancomycin MIC and genotypic detection of the van A resistance 
type. Similar to our study, Suzanne et al94 shave reported 100% concordance of 
these two methods for the detection of van A VRE. Whereas Perlada.D et al78 have 
reported 95% concordance in their study which is lower than that of our study. But 
discrepancies between phenotypic & genotypic detection of van A, van B were 
shown in their study done by Ira prahraj et al87, Rengaraj et al9 .  
In our study as per table 21, characteristics of vancomycin resistant 
Enterococci were discussed. Among 6 VRE isolates, vancomycin was resistant to 
all 6 isolates by both, disc diffusion method, Screen agar method. Four VRE 
isolates were resistant to Teicoplanin by disc diffusion method.  We determined 
MIC by E-strip method which showed all 6 isolates were resistant to Vancomycin 
& 4 were resistant to Teicoplanin and we studied genotyping  using  PCR. It 
showed 4isolates were positive for van A genotype and 2 isolates were positive for 
van B genotype. It is similar to studies done by Ira prahraj et al87,   Purva Mathur et 
al86 where they isolated van A genotype predominantly. van A is the most common 
genotype isolated in most of the studies including our study but in the studies done 
by Rengaraj et al9, Ghosh(Ray) Reena et al88  it was in contrast  and van B gene was 
the most common gene isolated. Also in a study done by Kamarkar et al66 they 
detected only van B gene from their 12 VRE isolates. 
As per table 22, we observed the antibiotic susceptibility pattern of  all VRE 
isolates with Linezolid, Quinpristin/Dalfopristin, Tigecycline using disc diffusion 
method. Interpretations were made by using CLSI 2015 & EUCAST 2015( for 
Tigecycline) guidelines. It showed that all the isolates were100% susceptibile to 
Linezolid and Tigecycline. Quinpristin/Dalfopristin was 100% sensitive to 
E.faecium producing VRE isolates. It was in concordance with Varsha Gupta et al3 
where they observed 100% susceptibility to Linezolid, Tigecycline, but reported 
resistance to Quinpristin/Dalfopristin in 2 of their isolates. In another study done by 
Manoharan et al95 where they showed similar findings as 100% susceptibilty to 
Tigecycline to all their VRE isolates. In a study done by Vidyalakshmi PR et al96 
they showed 100% susceptibility to Linezolid, Tigecycline. Linezolid resistance 
was reported in studies done by S.Rai et al97, Maj Puneet Bhatt et al90, and Yasliani 
et al98.  Nonika Rajkumari et al92 observed Linezolid and Quinpristin/Dalfopristin 
resistance in E.faecalis in their study.  
Enterococci infection is really a concern for health care institution99. 
Enterococci may act as a reservoir for vancomycin resistance genes that could be 
transferred to more virulent bacteria, such as Staphylococcus aureus 11 Early 
detection of VRE and adherence to strict infection control measures will help in 
effective management and in preventing spread of Vancomycin resistant 
Enterococci100. Slowing the spread of vancomycin resistant Enterococci (VRE) 
colonisation and infection, therefore, should remain a high priority for health care 
institutions. 
SUMMARY 
 Enterococci have emerged as important nosocomial pathogens with a 
capacity to cause a variety of infections and emergence of resistance to many 
of the antibiotics has made their management difficult. 
 In this study, a total of 240 Enterococcal isolates were recovered from 
various clinical specimens. Majority of the isolates were from Urine 
131(54.58%), followed by Pus 60(25%), Blood 31(12.92%), High vaginal 
Swab 18(7.50%) 
 Among the isolates 25.83% were from 46-60 yrs age group followed by 
25.42% in 15-30yrs, 23.33% in 30-45 yrs and 12.08% in 60-75 yrs. Isolates 
were more from male (53.75%) than female patients (46.25%). 
 The isolates were speciated by conventional tests, of which E.faecalis is the 
predominant species 150(62.50%) isolated, followed by E.faecium 
78(32.50%), E.raffinosus 6(2.50%), E.avium 3(1.25%), E.durans 2 (0.83%), 
E.hirae 1(0.42%). 
 About 31 (12.92%) Enterococcal isolates were from intensive care units.  
 Enterococci were isolated more from burns wound (13.75%) followed by 
Urinary catheterization (12.92%), Diabetes (9.58%), Post operative infection 
(5%), Septicemia (4.17%) 
 Hemolysin 30(20%), Gelatinase 42(28%), Biofilm 78(52%) were produced 
by E.faecalis & Hemolysin 14(18%), Gelatinase 20(25.64%), Biofilm 
33(42.30%) were produced by E.faecium. Virulence factors were produced 
more in Post operative wound infection followed by Burns wound infection, 
Septicemia, Diabetes, Urinary tract infections. 
  Antibiotic susceptibility was done by Kirby bauer disc diffusion method. 
E.faecalis isolates showed highest resistance to Penicillin 82.05% and least 
resistance to Teicoplanin 0.67% ,Vancomycin 1.33%. No resistance was 
seen with Linezolid and Tigecycline. E.faecium showed highest resistance to 
Penicillin 76% and least resistance to Teicoplanin 3.85% and Vancomycin 
5.13%s. No resistance was seen with Linezolid, Quinipristin/Dalfopristin 
and Tigecycline. 
 High Level Aminoglycoside Resistance was observed among 43 isolates 
(28.67%) in E.faecalis  and among 40 isolates (51.28%) in E.faecium 
 About 6 isolates (2.5%) were identified presumptively as vancomycin 
resistant by using Vancomycin screen agar containing 6μg/ml vancomycin. 
 All the 6 isolates were tested for MIC for both Vancomycin & Teicoplanin 
by E-strip method, which showed all 6 isolates were resistant to Vancomycin 
(≥32µg/dl) and 4 isolates were resistant to Teicoplanin (≥16µg/dl).  . 
 MIC determination of Vancomycin using agar dilution method showed all 
those 6 isolates were resistant to Vancomycin (≥32µg/dl). 
 About 4 VRE isolates showed MIC ≥64μg/ml for Vancomycin and 
≥16μg/ml for teicoplanin and were identified as of van A Phenotype. The 
remaining 2 isolates showed Teicoplanin MIC in the range of 0.5-1μg/ml 
and were identified as van B Phenotype  
 In PCR study, 4 vancomycin isolates showed van A gene and 2 isolates 
showed van B gene. van A was the commonest  in both phenotypic & 
genotypic  detection methods of Vancomycin resistance. 
 We found in our study, 100% concordance between Phenotypic 
classification by Vancomycin MIC detection and molecular genotyping for 
the detection of     van A type & van B type of VRE. 
 All the 6 VRE isolates were sensitive to Linezolid and Tigecycline. All the 4 
isolates of vancomycin resistant E.faecium were sensitive to Quinupristin 
and Dalfopristin. 
 
Enterococci have a incredible ability to survive in an environment of heavy 
antibiotics. Infact, it is their resistance to multiple antibiotics that makes them such 
feared opponents. Hence it warrants regular surveillance of antibiotic resistance of 
Enterococci and  the implementation of an efficient infection control program in 
order to establish a rational antibiotic policy for the better management of 
Enterococcal infections. 
 
 
 
CONCLUSION 
Enterococci have become emerging nosocomial pathogens leading to 
complications, prolonged recovery or increased case fatality 
 In our study we isolated a total of 240 Enterococcal isolates from various 
clinical samples among which E.faecalis and E.faecium were the 
predominant species isolated.  
 Virulence factors like Hemolysin 44(18.33%), Gelatinase 62(25.83%), 
Biofilm 114(47.5%) were produced. 
 They showed resistance to multiple antibiotics and all isolates were sensitive 
to Linezolid, Tigecycline, Quinipristin/ Dalfopristin    
 6  isolates of which 4 isolates were E. faecium & 2 isolates were E.faecalis,  
were identified as Vancomycin Resistant Enterococci with a prevalence rate 
of about 2.5% as per  Vancomycin MIC and by PCR assay.   
 In PCR study, van A gene was detected in 4 isolates and 2 isolates showed     
van B gene which was in concordance with both phenotypic & genotypic 
method of detection. 
The present study showed emerging resistance of Enterococci which may 
lead to increase in  morbidity & mortality that can be controlled by strict 
enforcement of antibiotic policy coupled with strict adherence to infection control 
measures to prevent further emergence and spread of antibiotic resistance.  
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MacConkey Agar: 
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Hemolysin Production: 
Gelatinase Production: 
Biofilm Formation: 
Antibiotic Susceptibility Pattern:  
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சுய ஒப்புதல் படிவம் 
ஆய்வு செய்யப்படும் தலைப்பு: SPECIATION, CHARACTERIZATION AND ANTIBIOTIC 
SUSCEPTIBILITY PATTERN OF ENTEROCOCCI FROM CLINICAL ISOLATES IN A TERTIARY CARE 
HOSPITAL 
ஆய்வு செய்யப்படும் இடம்: கீழ்பாக்கம் அரசு மருத்துவக்கல்லூரி மற்றும்                                            
மருத்துவமலை, சென்லை-10 
பங்கு சபறுபவரின் சபயர்: 
பங்கு சபறுபவரின் வயது:                           பங்குசபறுபவரின் எண் : 
 
 மமமை குறிப்பிட்டுள்ள மருத்துவ ஆய்வின் விவரங்கள் எைக்கு 
விளக்கபட்டுள்ளது. நான் இவ்வாய்வில் தன்ைிச்லெயாக பங்மகற்கின்மறன். 
எந்த காரணத்திைாமைா, எந்த ெட்ட ெிக்கலுக்கும் உட்படாமல் நான் 
இவ்வாய்வில் இருந்து விைகிக் சகாள்ளைாம் என்றும் அறிந்துசகாண்மடன். 
 இந்த ஆய்வு ெம்பந்தமாகமவா, இலத ொர்ந்து மமலும் ஆய்வு 
மமற்சகாள்ளும் மபாதும் இந்த ஆய்வில் பங்குசபறும் மருத்துவர் 
என்னுலடய மருத்துவர் என்னுலடய மருத்துவ அறிக்லககலள பார்ப்பதற்கு 
என் அனுமதி மதலவ இல்லை எை அறிந்து சகாள்கிமறன். இந்த ஆய்வின் 
மூைம் கிலடக்கும் தகவலைமயா,முடிலவமயா பயன்படுத்திக் சகாள்ள 
மறுக்கமாட்மடன். 
 இந்த ஆய்வில் பங்கு சகாள்ள ஒப்புக் சகாள்கிமறன். இந்த ஆய்லவ 
மமற்சகாள்ளும் மருத்துவ அணிக்கு உண்லமயுடன் இருப்மபன் என்று 
உறுதியளிக்கிமறன். 
பங்மகற்பவரின் லகசயாப்பம்:                 ொட்ெியாளரின் லகசயாப்பம் 
இடம்:                                                                                      இடம்: 
மததி:                                                                                      மததி : 
பங்மகற்பவரின் சபயர் மற்றும் விைாெம்: 
 
ஆய்வாளரின்  லகசயாப்பம்: 
இடம்:                                    மததி:                   
  
PATIENT CONSENT FORM 
 
STUDY DETAIL: SPECIATION, CHARACTERIZATION AND ANTIBIOTIC SUSCEPTIBILITY 
PATTERN OF ENTEROCOCCI FROM CLINICAL ISOLATES IN A TERTIARY CARE HOSPITAL 
 
STUDY CENTER: KILPAUK MEDICAL COLLEGE AND HOSPITAL, CHENNAI. 
PATIENT NAME:     PATIENT AGE: 
IDENTIFICATION NUMBER: 
PATIENT TO TICK (        ) THESE BOXES  
 
I conform that I have understood the purpose of procedure for the above study.  
I have the opportunity to ask the question and all my questions and doubts have been 
answered to my satisfaction. 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at anytime without giving any reasons, without my legal rights being affected. 
I understand that investigator, regulatory authorities and the ethics committee will not 
need my permission to look at my health records both in respect to the current study and 
any further research that may be conducted in relation to it, even if withdraw from the 
study, I understand that my identity will not be revealed in any information released to 
third parties or published, unless as required under the law. I agree not to restrict the use 
of any data or results that arise from the study. 
 
I agree to take part in the above study and to comply with the instructions given during 
the study and faithfully cooperative with the study team and immediately inform the 
study staff if I suffer from any deterioration in my health or wellbeing or any unexpected 
or unusual symptoms. 
I hereby give consent to participate in this study. 
I hereby give permission to undergo complete clinical examination and diagnostic test. 
 
Signature/Thumb impression:    Place:   Date: 
Patient name and address: 
 
Signature of the investigator:    Place:   Date: 
Study investigator’s name: 
APPENDIX 
 
PEPTONE WATER 
Peptone                        - 10g 
Sodium chloride                 - 5g 
Distilled water                     - 1 litre 
 
Dissolve the ingredients in warm water, adjust the pH to 7.4 -7.5 and filter. 
Distribute as required and autoclave at 121 degree Celsius for 15 mins. 
 
BLOOD AGAR 
Sterile sheep blood   -  50 ml 
Peptone     - 10 g 
Beef extract     - 3g 
Sodium chloride   -  5 g 
Distilled water    - 1000 ml 
 
Autoclave the nutrient agar base at 121º C for 15 minutes and blood with sterile 
precautions and distribute in Petri dishes. 
 
MAC CONKEY AGAR 
 
Peptic digest of animal tissue  -  17g 
Proteose peptone    -  3g 
Lactose    -  10g 
Bile salts    -  1.5g 
Sodium chloride    -  5g 
Neutral red     -  0.03g 
Agar     -  15g 
Distilled water   - 1000 ml 
 
 Final pH at (25º C) 7.1±0.2.  
 
 Suspend 51.53 grams in 1000 ml of distilled water. Heat to boiling to 
dissolve the medium completely. Sterilize by autoclaving at 15 lbs pressure (121ºC) 
for 15 minutes. Mix well and pour into Petri dish plates. 
 
NUTRIENT AGAR 
 
Peptic digest of animal tissue   - 5g 
Beef extract     - 1.5g 
Yeast extract     - 5g 
Agar       - 15g 
Distilled water     - 1000ml 
 
 Dissolve the contents in water and mix by heating. Autoclave at 121° C for 
15 minutes. Adjust pH to 7.4 + 0.2. Pour 20-25 ml of 9 cm dia. Petri dishes to give 
4 mm thickness 
BILE ESCULIN AGAR: 
Peptone     -  5 gm 
Beef extract    - 3gm 
Oxgall(bile)    - 40gm 
Esculin     - 1gm 
Ferric citrate    - 0.5gm 
Agar     - 15gm 
Distilled water    - 1 L 
Final pH 7.0 
 Heat to dissolve the contents completely, sterilize at autoclave at 121ºC for 
10 minutes, pour into slants/ Petri plates. 
 
BRAIN HEART INFUSION BROTH:- 
Calf brain infusion   - 200g 
Beef heart infusion   - 250g 
Proteose peptone    - 10g 
Dextrose    -  2g 
Sodium chloride    - 5g 
Disodium phosphate  -  2.5g 
Distilled water    - 1000ml 
 
 Add the contents and dissolve by heating.  Adjust the pH to 7.4 + 0.2. 
Autoclave at 121° C for 15 minutes. 
6.5% NaCl BROTH: 
 
Nutrient broth    -  1L 
NaCl    -  6.5gm 
 
 Dissolve the contents completely, autoclave at 121ºc for15 min and 
distribute in tubes. 
 
MUELLER HINTON AGAR: 
 
Beef infusion    -  300g  
Casein acid hydrolysate   -  17.5g  
Starch     - 1.5g 
Agar      - 17g 
Distilled water    - 1000ml 
Final pH at 25º C 7.4. 
 
 Suspend 38 Gms in 1000 ml of distilled water. Heat to boiling to dissolve the 
medium completely. Sterilize by autoclaving at 15 lbs pressure (121ºC) for 15 
Minutes. Mix well and pour 20-25 ml of it into Petri dishes of 90 mm diameter to 
depth of 4 mm of medium. 
 
MCFARLAND TURBIDITY STANDARD FOR INOCULUM 
PREPARATION 
 
A Barium sulphate 0.5 McFarland standard was prepared as follows 
 
1. A 0.5 ml of 0.048mol/L of Barium chloride was added to 99.5 ml of 0.18 
mol/L of H2SO4 with constant stirring to maintain a suspension.  
 
2. Correct density of the turbidity standard was verified by using a 
spectrophotometer. The absorbance of 625nm should be 0.08 to 0.10 for 
the 0.5 McFarland standards. 
 
3. The Barium sulphate suspension was transferred in 4-6 ml to a screw 
capped tube of the same size as those used in growing or diluting the 
bacterial inoculum. 
 
4. These tubes were tightly sealed and stored in the dark at room 
temperature. 
 
5. The Barium sulphate turbidity standard was vigorously agitated before 
each use and inspected for a uniform turbid appearance 
TABLE. 1. ZONE DIAMETER INTERPETIVE STANDARDS FOR 
ENTEROCOCCUS SPECIES. (CLSI GUIDELINES 2015) 
 
Antimicrobial 
agent 
Disk 
content 
Zone diameter 
Interpretative criteria ( Nearest whole mm) 
Sensitive Intermediate Resistant 
Penicillin G 10units ≥15 - ≤14 
Ampicillin 10μg ≥17 - ≤16 
Erythromycin 15μg ≥23 14-22 ≤13 
Doxycycline 30μg ≥16 13-15 ≤12 
Ciprofloxacin 5μg ≥21 16-20 ≤15 
Levofloxacin 5μg ≥17 14-16 ≤13 
Nitrofurantoin 300μg ≥17 15-16 ≤14 
High level 
Gentamicin 
120μg ≥10 7-9 ≤6 
High level 
Streptomycin 
300μg ≥10 7-9 ≤6 
Vancomycin 30μg ≥17 15-16 ≤14 
Teicoplanin 30μg ≥14 11-13 ≤10 
Linezolid 30μg ≥23 - ≤20 
Quinpristin / 
Dalfopristin 
15μg ≥19 16-18 ≤15 
 
 
  
TABLE-2. ZONE DIAMETER INTERPETIVE STANDARDS FOR 
ENTEROCOCCUS SPECIES. (EUCAST GUIDELINES 2015) 
 
 
Antimicrobial 
agent 
Disk 
content 
Zone diameter 
Interpretative criteria ( Nearest whole mm) 
Sensitive Intermediate Resistant 
Tigecycline 15μg ≥19 - ≤16 
 
 
 
 
TABLE-3 MIC INTERPRETIVE STANDARDS FOR ENTEROCOCCUS SPP. 
(CLSI GUDELINES 2015) 
 
 
Antimicrobial 
Agents  
MIC Interpretive Criteria (μg/mL)  
Sensitive Intermediate Resistant 
Vancomycin ≤4 8-16 ≥32 
Teicoplanin ≤8 16 ≥32 
 
 
 
 
 
 
  
ABBREVIATION 
ATCC   - American Type Culture Collection 
AFLP   -  Amplified-Fragment Length Polymorphisms 
CAPD   - Chronic Ambulatory Peritoneal Dialysis 
CFU   - Colony Forming Units. 
CLED   - Cystine Lactose Electrolyte Deficient  
CLSI   - Central Laboratory Standards Institute 
CVC   - Central Venous Catheters 
ELISA  - Enzyme Linked Immunosorbent Assay 
E- TEST  - Epsilometer Test 
FDA   - Food and Drug Administration (United States   
    USFDA) 
HLAR  - High Level Aminoglycoside Resistance 
HLG   - High Level Gentamicin 
HLS   - High Level Streptomycin 
ICU   - Intensive Care Unit 
OPD   - Out Patient Department 
MALDI –TOF - Matrix Assisted Laser Desorption/Ionisation –                                            
    Time of Flight. 
MDR   - Multi Drug Resistance 
MHA   - Mueller Hinton Agar 
MIC   - Minimum Inhibition Concentration 
MLST   - Multi-locus Sequence Typing 
MLVA  - Multiple Locus Variable Number of Tandem   
    Repeat Analysis 
MRSA  - Methicillin Resistant Staphylococus aureus 
MRSE  - Methicillin Resistant Staphylococus epidermidis 
MSSA  - Methicillin Sensitive Staphylococus aureus 
MSCRAMM - Microbial Surface Components Recognizing      
 Adhesive Matrix Molecules 
NGS   -  Next Generation Sequencing 
PCR   - Polymerase Chain Reaction 
PFGE   - Pulsed-Field Gel Electrophoresis 
PPE   - Personal Protective Equipments 
PYR   - α-pyrrolidonyl β-naphthylamide 
UTI   - Urinary Tract Infection 
VRE   - Vancomycin Resistant Enterococci 
VISA   - Vancomycin Sensitive Staphylococcus aureus 
VRSA   - Vancomycin Resistant Staphylococcus aureus 
 
 
 
  
KEY TO MASTER CHART 
 
M   - Male patient 
F   - Female patient 
IP   -  Inpatient  
OP   -  Outpatient 
M (AGE)  - Months 
D (AGE)  - Days 
OG   -  Obstetrics & Gynecology 
LBW   - Labour Ward 
ART CENTER - Anti Retroviral Therapy Center 
ICU   - Intensive Care Unit 
NICU   -  Neonatal Intensive Care Unit 
PICU   -  Pediatric Intensive Care Unit 
BICU   -  Burns Intensive Care Unit 
IMCU   -  Intensive Medical Care Unit 
BPH   - Benign Prostatic Hypertrophy 
UTI   -  Urinary tract infection 
POI   - Post Operative Infection 
CKD   -  Chronic Kidney Disease 
PUO   -  Pyrexia of unknown origin 
PO-TURP  - Post Opeartive -Trans Uretheral Resection of   
    Prostate 
HVS   - High Vaginal Swab 
P   - Produced 
NP   -  Not Produced 
S   -  Susceptible 
R   - Resistant 
NA   - Not Applicable 
PEN – G  - Penicillin G 
AMP   - Ampicillin 
E   - Erythromycin 
CIP   - Ciprofloxacin 
LE   - Levofloxacin 
NIT   - Nitrofurantoin 
HLG   - High Level Gentamicin 
HLS   - High Level Streptomycin 
VA   - Vancomycin 
TEI   - Teicoplanin 
LZ   - Linezolid 
TIG   - Tigecycline 
RP   - Pristinomycin 
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1 1025 OP 33 24 F Medical OP UTI Urine E.faecalis P NP P S R S R S S S S S S S S S NA 
2 3527 IP 58 36 M Surgery POI 
Urine(Cathete
rised) 
E.faecium P P P S S S S S S S R R S S S S S 
3 1319464 OP 61 60 F Medical OP Diabetes Urine E.faecalis NP P P R S R R S S S R S S S S S NA 
4 1441338 OP 69 56 M Medical OP Fever Urine E.faecalis NP NP NP R R S S R S S S S S S S S NA 
5 1032/14 IP 75 60 M Nephrology UTI 
Urine(Cathete
rised) 
E.faecalis P NP P S S S R R S S R R S S S S NA 
6 843/14 IP 78 80 F Nephrology UTI Urine E.faecalis NP NP NP R R S R S R S S R S S S S NA 
7 21/15 IP 110 49 M Nephrology CKD Urine E.faecium P NP NP R R S R R R R R R S S S S S 
8 10061 OP 112 49 M Medical OP Diabetes Urine E.faecium NP NP P R R S S R S S S S S S S S S 
9 144/90 OP 161 22 F Nephrology UTI Urine E.faecalis NP NP P R S R R S S S S R S S S S NA 
10 4420 IP 174 55 F Medicine Fever Urine E.faecium NP NP NP R S S S S S S S S S S S S S 
11 144155 OP 198 19 M Medical OP PUO Urine E.faecalis NP NP NP R S R R R R S S S S S S S NA 
12 1438819 IP 230 41 M Urology POP-TURP 
Urine 
(Catheterised) 
E.faecium NP P P R R R R R R R R R S S S S S 
13 1440060 IP 272 44 M Nephrology UTI Urine E.faecalis NP NP P R R S R R R S R R S S S S NA 
14 2371 OP 284 48 M Urology UTI/CKD Urine E.faecalis P P P S S S R R S S S S S S S S NA 
15 9783 IP 317 40 F Medicine PUO 
Urine 
(Catheterised) 
E.faecalis NP NP NP R R R S R R R R R S S S S NA 
16 86/15 OP 348 52 M Urology UTI Urine E.faecalis NP NP NP S R S R R R S R S S S S S NA 
17 8388 IP 365 25 M Surgery POI 
Urine 
(Catheterised) 
E.faecalis P P P R R R S R S R R R S R S S NA 
18 1673 IP 392 60 M Nephrology CKD Urine E.faecalis NP NP P R R S R R R R R R S R S S NA 
19 1968 OP 437 40 M Urology UTI Urine E.faecium NP NP NP R R S R R R S R S S S S S S 
20 1875 OP 447 60 F Medicine PUO 
Urine 
(Catheterised) 
E.faecalis P NP NP R R S R S S S S S S S S S NA 
21 2142 IP 454 51 F Medicine UTI Urine E.faecalis NP P P S S S R S S S R R S R S S NA 
22 2495 IP 458 55 M Urology UTI 
Urine 
(Catheterised) 
E.faecalis NP NP NP R R S R R R S S R S R S S NA 
23 113/15 IP 486 44 M Urology UTI 
Urine 
(Catheterised) 
E.faecium NP NP P R R R R R R R R R S R S S S 
24 575 IP 513 20 F OG PUO Urine E.faecalis NP NP NP S S R R R S R R R S R S S NA 
25 536 OP 537 30 M Medical OP PUO Urine E.faecalis NP P NP R R R R R R S R R S R S S NA 
26 2397 OP 618 55 F Medical OP Diabetes Urine E.faecium NP NP NP R R S R R R S R R S R S S S 
27 2896 OP 619 25 M Medical OP UTI Urine E.avium NP NP NP R R S R R S S R R S S S S S 
28 2715 OP 654 45 M Medical OP PUO Urine E.faecium NP NP NP R R S R R S S S R S R S S S 
29 2105 OP 662 38 F Medical OP Fever Urine E.faecalis NP NP NP R R S R R R S R R S R S S NA 
30 2622 IP 705 55 M Medicine UTI Urine E.durans NP NP NP R R S R R S S S S S S S S S 
31  2204 OP 710 60 M Medical OP PUO Urine E.faecium NP NP NP R R S S R S S S R S R S S S 
32 1284712 OP 752 22 F Medical OP PUO Urine E.faecalis NP NP NP R R S S R R S S R S R S S NA 
33 3224 IP 757 
5
M 
MC
H 
Pediatrics Fever Urine E.faecalis NP NP NP R R R R R R S S R S R S S NA 
34 20048 IP 766 34 F Surgery UTI Urine E.raffinosus NP NP NP S S S S S S S S S S S S S S 
35 20060 IP 798 35 M Surgery Fever 
Urine 
(Catheterised) 
E.faecalis P P P R R S R R R S R R S S S S NA 
36 14223 OP 847 47 M Surgery UTI Urine E.faecalis P NP P R R S R R R R R R S S S S NA 
37 3428 OP 853 62 M Urology PUO 
Urine 
(Catheterised) 
E.faecalis NP NP P S S S S S S S S R S S S S NA 
38 3204 IP 900 25 F OG Fever Urine E.faecium NP NP NP R R S S R R S R R S S S S S 
39 2197 IP 962 36 M ART Center Diarrhea Urine E.faecalis NP NP NP R R R R R R S R R S S S S NA 
40 3211 OP 965 62 M Nephrology UTI Urine E.faecalis P NP P R R R R R R S S R S S S S NA 
41 1109 OP 1070 40 M Urology UTI Urine E.faecalis NP P NP R R S R R R S S R S S S S NA 
42 208/15 IP 1082 63 M Nephrology PUO 
Urine 
(Catheterised) 
E.faecalis NP NP NP R R R R S S S S R S S S S NA 
43 4322 IP 1097 49 M Urology UTI 
Urine 
(Catheterised) 
E.faecalis NP NP P S S R R S S S R R S R S S NA 
44 4321 IP 1100 65 M Urology UTI Urine E.faecalis P NP NP R R R R R R R R S S S S S NA 
45 3320 IP 1124 6 
MC
H 
Pediatrics PUO Urine E.faecalis NP P NP R R R R R R R R R S R S S NA 
46 30051 IP 1154 55 F Surgery POI 
Urine 
(Catheterised) 
E.faecium P NP P R R R R R S S S S S S S S S 
47 117862 OP 1174 63 F Medical OP Fever Urine E.faecalis NP P NP S S S S S S S S R S S S S NA 
48 4359 OP 1192 47 M Medical OP Fever Urine E.hirae NP NP NP R R R R R S S R R S S S S S 
49 327/15 IP 1196 68 F Urology 
UTI 
(Catheteri
sed) 
Urine E.faecalis NP NP P R R R R R R R R R R S S S NA 
50 31860 OP 1212 11 
MC
H 
Pediatrics Fever Urine E.faecalis NP NP NP R R R R R R R S S S S S S NA 
51 4741 OP 1228 23 M Urology UTI 
Urine 
(Catheterised) 
E.faecalis NP NP P R R S R R S S R R S S S S NA 
52 236/15 OP 1231 48 M Nephrology PUO 
Urine 
(Catheterised) 
E.faecalis NP P NP R R S S R R S R R S S S S NA 
53 335 OP 1234 48 M Urology Diabetes 
Urine 
(Catheterised) 
E.faecalis P NP P S S S S S S S S S S S S S NA 
54 5502 IP 1257 30 F OG/LBW UTI Urine E.faecalis NP NP NP S S S R S S S S R S S S S NA 
55 32275 IP 1266 33 M Surgery UTI Urine E.faecalis NP P P S S S S S S S S R S S S S NA 
56 5133 OP 1280 70 F Medical OP Fever Urine E.faecalis NP NP P S S S S S S S S S S S S S NA 
57 5102 OP 1292 40 M Urology UTI 
Urine 
(Catheterised) 
E.faecium NP NP NP R R R R R S S S R S S S S S 
58 4381 IP 1322 36 F Medicine PUO Urine E.raffinosus NP NP NP R S S S S S S R R S S S S S 
59 112/15 OP 1336 47 M Nephrology UTI Urine E.faecalis P NP P S S S S S S S S S S S S S NA 
60 352 IP 1438 3 
MC
H 
Pediatric 
ICU 
PUO Urine E.faecium NP NP NP R S R R R R S R S S S S S S 
61 863 IP 1469 61 M Urology Post TURP 
Urine 
(Catheterised) 
E.faecalis P NP P R R R R R R S S R S S S S NA 
62 417/15 IP 1470 45 M Urology UTI Urine E.faecalis NP P NP R R R R S S S R R S S S S NA 
63 3214 IP 1514 70 F OG 
Post 
Hysterect
omy 
Urine E.faecium P NP P R R R R R S S R R S S S S S 
64 424 OP 1560 59 M Urology Fever 
Urine 
(Catheterised) 
E.faecalis NP NP NP R R R S R R S R R S S S S NA 
65 42418 IP 1591 52 F Surgery UTI Urine E.faecalis NP NP P S S S R S S S S R S S S S NA 
66 431 OP 1604 24 F Medicine PUO Urine E.faecalis NP NP NP S S S R S S S S S S S S S NA 
67 5555 OP 1612 60 F Urology UTI Urine  E.faecalis NP P P R S R R R R S S R S S S S NA 
68 769 OP 1620 34 F Medicine PUO Urine E.raffinosus NP NP NP R R S R R R S R R S S S S S 
69 463 OP 1643 21 M Urology UTI Urine E.faecium NP NP NP S R S S S S S R R S S S S S 
70 613 IP 1647 62 F Medicine UTI Urine E.faecalis P NP P R R R R R R R R R S S S S NA 
71 412 OP 1648 62 F Urology 
Renal 
Calculi 
Urine E.faecium NP NP NP R R R R R S S R S S S S S S 
72 798 OP 1655 49 M Nephrology 
Renal 
Calculi 
Urine E.faecalis NP NP P R R R R R R R R R S S S S NA 
73 795 IP 1701 50 F IMCU 
Diabetic / 
UTI 
Urine 
(Catheterised) 
E.faecium NP P P R R S R R S S R R S S S S S 
74 5650 IP 1720 5 
MC
H 
Pediatrics PUO Urine E.faecalis P NP NP R R S R S S S R S S S S S NA 
75 45902 IP 1728 14 M Surgery UTI 
Urine 
(Catheterised) 
E.raffinosus NP NP P R R R R R R R R R S S S S S 
76 5713 IP 1731 39 M Nephrology 
Renal 
Calculi 
Urine E.faecium NP NP P R R R R R R R R R S S S S S 
77 1962 IP 1739 38 F OG UTI Urine E.faecium NP NP NP R R R R S S S S R S S S S S 
78 496/15 IP 1761 12 
MC
H 
Urology 
Renal 
Calculi 
Urine E.faecalis NP NP P S S R R S S S S R S R S S NA 
79 2142 OP 1772 31 M Medical OP UTI Urine E.faecium NP NP NP R S R R R R S R R S R S S S 
80  31854 OP 1773 3 
MC
H 
Pediatrics 
Fever For 
Evaluation 
Urine E.faecalis NP NP NP R S R R R R R R R S S S S NA 
81 6184 IP 1846 62 M Medicine PUO Urine E.faecium NP NP P R S R R R S S R R S S S S S 
82 5120 IP 1898 24 F Urology 
Renal 
Calculi 
Urine E.faecium NP NP NP R R R R R R R R R S S S S S 
83 3612 OP 1900 63 M Medical OP UTI Urine E.faecalis NP NP P R S R R R R S R R S S S S NA 
84 6413 OP 1901 27 F Medical OP 
Fever For 
Evaluation 
Urine E.faecalis NP NP NP R S S R R R S R R S S S S NA 
85 25608 IP 1913 50 F Medical OP UTI Urine E.faecalis NP NP NP R R R S S S S S S S S S S NA 
86 558/15 IP 1944 56 F Urology 
Renal 
Calculi 
Urine E.faecium P NP NP R S R R R R R R R S S S S S 
87 42354 IP 1952 64 M Surgery 
POI -UTI -
Appendici
tis 
Urine 
(Catheterised) 
E.faecium P P P R R R R R R R R R R R S S S 
88 1230 IP 1962 70 F Surgery 
Renal 
Calculi 
Urine E.faecalis NP NP P R S R R S S R R R S R S S NA 
89 6609 IP 1988 50 M Medicine 
Diabetes/
UTI 
Urine E.faecium NP NP NP R S S R R R R R R S R S S S 
90  31960 IP 1990 2 
MC
H 
Pediatrics 
Fever For 
Evaluation 
Urine E.faecalis NP NP NP R R R R S S S R R S R S S NA 
91 10400 OP 2020 77 F Surgery 
Stress 
Incontine
nce 
Urine E.faecalis NP NP NP R S S R R S S S S S S S S NA 
92 885 IP 2021 55 M Medicine 
Diabetes-
UTI 
Urine E.faecium NP NP P R R R R R R R R R R R S S S 
93 45/15 IP 2027 79 M Urology PO-TURP 
Urine 
(Catheterised) 
E.faecalis P P P R R R R R R S R R S R S S NA 
94 56015 Op 2059 28 M Medical OP UTI Urine E.faecalis NP NP P R S S R R S S R R S R S S NA 
95 6986 OP 2061 24 f Nephrology UTI Urine E.faecalis NP NP P R R S S S S S R S S S S S NA 
96 65022 IP 2140 42 M Urology 
Renal 
Calculi 
Urine E.faecalis NP NP NP S S S S S S S S R S S S S NA 
97 58895 IP 2150 60 F OG 
Stress 
Incontine
nce 
Urine E.faecalis NP NP NP R S R R S S S S R S S S S NA 
98 7153 IP 2155 58 F Medicine UTI Urine E.faecalis NP NP P R R S R R S R R R S S S S NA 
99 6471 IP 2160 30 M Urology 
Renal 
Calculi 
Urine E.faecalis P P NP R R S S S S S R R S S S S NA 
100 7377 IP 2183 73 M Urology Prostatitis Urine E.faecalis P NP P R R R R R R R R R S S S S NA 
101 7334 IP 2185 57 M Urology 
Stress 
Incontine
nce 
Urine E.faecium NP NP NP S S S S S S S S S S S S S S 
102 7378 OP 2187 59 M Medical OP UTI Urine E.faecium NP NP NP R R R R R R R R S S S S S S 
103 7212 OP 2194 80 M Urology 
BPH 
Prostate 
Urine E.faecalis NP NP NP R R R R R S R R R S S S S NA 
104 7387 IP 2200 53 F OG 
Stress 
Incontine
nce 
Urine E.faecalis NP NP P R R R S R S S R R S S S S NA 
105 63950 IP 2262 65 M Surgery 
Renal 
Calculi 
Urine E.faecalis NP NP NP R R S S R R R R S S S S S NA 
106 657 IP 2270 80 M Surgery UTI 
Urine 
(Catheterised) 
E.faecalis NP NP P R R S R R S S S R S S S S NA 
107 2181 IP 2273 27 F Urology 
Renal 
Calculi 
Urine E.faecalis NP NP NP R R S R R R S S S S S S S NA 
108 3848 OP 2301 27 M Medical OP UTI Urine E.faecalis NP NP P R R R R R R R R R S S S S NA 
109 52355 IP 2324 45 F Surgery UTI Urine E.faecalis P NP P R S S S S S S R R S S S S NA 
110 7918 IP 2340 54 F Medicine Diabetes Urine E.faecium NP NP P R R R R R R S S R S S S S S 
111 8015 IP 2349 59 M Ortho 
Traumatic 
Wound 
Urine 
(Catheterised) 
E.faecium P P P R R R R R R R R R S S S S S 
112 7605 IP 2421 22 F OG/LBW 
Fever For 
Evaluation 
Urine E.faecalis NP NP NP R R R R R R R R R S S S S NA 
113 8272 IP 2433 5 FCH Pediatrics 
Fever For 
Evaluation 
Urine E.faecalis P P NP R R R R R R R S S S S S S NA 
114 7089 IP 2503 30 F OG/ LBW 
Fever For 
Evaluation 
Urine E.faecalis NP NP NP R R S R R R R S R S S S S NA 
115 75344 IP 2574 35 F Surgery 
Dibetes / 
UTI 
Urine 
(Catheterised) 
E.faecalis P NP P S S S S S S S S R S S S S NA 
116 2958 OP 2623 35 M Medical OP Diabetes Urine E.avium NP NP NP R R R R S S S S S S S S S S 
117 80547 IP 2722 32 M Urology 
Renal 
Calculi 
Urine E.faecalis NP NP NP R S R R S S S R R R S S S NA 
118 78454 IP 2724 42 M Urology 
Renal 
Calculi 
Urine E.faecalis NP NP P R S R S S S S R R R S S S NA 
119 9590 OP 2776 10 
MC
H 
Pediatrics 
Fever For 
Evaluation 
Urine E.faecalis NP NP NP R R R R R R R S S S S S S NA 
120 9649 IP 2783 18 F OG UTI Urine E.faecalis P NP P S R S R S S S S R S S S S NA 
121 8432 IP 2852 75 M IMCU 
Diabetes/
UTI 
Urine 
(Catheterised) 
E.faecium P P P R R R R R R R R R S S S S S 
122 196 IP 2870 30 F Urology 
Renal 
Calculi 
Urine E.faecium NP NP NP S R S S S S S S R S S S S S 
123 3124 OP 2935 65 F Medical OP 
Fever For 
Evaluation 
Urine E.faecium NP NP NP R S S R S S S S S S S S S S 
124 10192 OP 2943 57 M Urology 
BPH 
Prostate 
Urine E.faecalis NP NP NP R S S R R S S R S S S S S NA 
125 3384 IP 2969 50 F OG 
Stress 
Incontine
nce 
Urine E.faecalis NP NP NP R S R R R R S R S S S S S NA 
126 10588 OP 2986 35 F Medical OP 
Fever For 
Evaluation 
Urine E.faecalis NP NP P R R S R R R S R S S S S S NA 
127 833/15 IP 2994 28 M Urology 
Renal 
Calculi 
Urine E.faecium NP NP P R S R R R R S R R S S S S S 
128 844/15 IP 3014 46 M Urology 
BPH 
Prostate 
Urine E.faecalis NP NP NP S S S S S S S S R S S S S NA 
129 4120 OP 3076 70 M Medical OP Prostatitis Urine E.faecium NP NP NP R R S R R R R R S S S S S S 
130 860/15 IP 3084 59 M Urology 
BPH 
Prostate 
Urine E.faecalis NP NP P S S S S S S S S R S S S S NA 
131 8709 OP 1609 57 M Surgery 
Wound 
Infection 
Pus E.faecalis P P NP R R S S R S S R S S S S S NA 
132 9935 OP 1759 48 F OG Vaginitis HVS E.faecalis NP NP NP R R R R R R R R S S S S S NA 
133 12013 IP 2042 48 F Burns Ward 
Burns 
Wound 
Wound Swab E.faecalis NP NP P R R S S S S S R R S S S S NA 
134 282/15 IP 2154 50 M Surgery POI Pus E.faecalis P NP P S S S S S S S S R S S S S NA 
135 3114 OP 2158 23 F OG Vaginitis HVS E.faecalis NP NP NP R S R R S S S R S S S S S NA 
136 12830 IP 2163 68 M Burns Ward 
Burns 
Wound 
Wound Swab E.faecalis NP P NP R R S S R S S R R S S S S NA 
137 14119 IP 2268 32 F BICU 
Burns 
Wound 
Wound Swab E.faecium NP NP NP S S S R S S S S R S S S S S 
138 12043 IP 2278 26 M BICU 
Burns 
Wound 
Wound Swab E.faecium P NP NP S S S S S S S S R S S S S S 
139 13772 IP 2304 37 M BICU 
Burns 
Wound 
Wound Swab E.faecalis NP NP P S S S S S S S S R S S S S NA 
140 13702 IP 2306 22 M BICU 
Burns 
Wound 
Wound Swab E.faecalis NP NP P S S S S S S S S R S S S S NA 
141 13422 IP 2335 36 F OG Vaginitis HVS E.faecalis NP NP NP R S R R R R R R S S S S S NA 
142 14721 IP 2463 23 F OG Vaginitis HVS E.faecalis NP NP NP R S S S S S S S S S S S S NA 
143 13902 IP 2469 60 M Surgery Peritonitis Pus E.faecalis P NP P R R R R R R R R R S S S S NA 
144 118674 IP 2540 70 M Surgery POI Pus E.faecium P NP P R S S R R R S R R S S S S S 
145 127331 IP 2681 50 M Ortho 
Wound 
Infection 
Pus E.faecium NP P P R S S R S S S S R S S S S S 
146 17388 OP 2768 21 F OG Vaginitis HVS E.faecalis NP NP NP R S S S S S S S S S S S S NA 
147 17427 OP 2771 26 F OG Vaginitis HVS E.faecalis P NP NP R S S R R S S R S S S S S NA 
148  14118 IP 2789 35 M Surgery 
Wound 
Infection 
Pus E.avium P NP P S S S S S R S S S S S S S S 
149 373 IP 1964 20 M Surgery 
POI-
Appendici
tis  
Pus E.faecalis NP P P R R R R R R R R R R R S S NA 
150 28131 IP 2248 64 F Burns Ward 
Wound 
Infection 
Pus E.faecalis NP NP P R R R R R R R R R S S S S NA 
151 18020 IP 2882 38 M Surgery 
Wound 
Infection 
Pus E.raffinosus P NP P S S S R R S S S S S S S S S 
152 17965 OP 2896 34 F OG Vaginitis HVS E.faecalis NP NP NP R S R S S S S R R S S S S NA 
153 18181 IP 2904 28 F Burns Ward 
Burns 
Wound 
Wound Swab E.faecalis P NP P S S S S S S S R R S S S S NA 
154 152290 IP 2935 17 M Surgery 
Wound 
Infection 
Pus E.faecalis NP NP P S S S S S S S S R S S S S NA 
155 18574 IP 2960 35 F Burns Ward 
Burns 
Wound 
Wound Swab E.faecium NP NP NP S S S S S S S S R S S S S S 
156 17170 IP 2968 25 M BICU 
Burns 
Wound 
Wound Swab E.faecalis NP NP NP S S S S S S S R R S S S S NA 
157 20212 OP 2985 18 M Medical OP 
Wound 
Infection 
Pus E.faecium NP NP NP S S S S S S S S S S S S S S 
158  613 IP 2987 51 M Ortho 
Wound 
Infection 
Pus E.faecalis NP NP P R S S R R S S R R S S S S NA 
159  18114 OP 3014 21 F OG Vaginitis HVS E.faecium NP NP NP R S R S S S S R S S S S S S 
160 18516 IP 3032 30 F OG 
Wound 
Infection 
Pus E.faecium P NP P R S S S S S S S R S S S S S 
161  18673 OP 3065 27 F OG Vaginitis HVS E.faecium NP NP NP S S S S S S S S S S S S S S 
162 19158 OP 3066 32 F OG Vaginitis HVS E.faecalis NP NP NP R R R R R R R R S S S S S NA 
163 20571 OP 3173 44 M Burns Ward 
Burns 
Wound 
Wound Swab E.faecalis P P P R R S R S S S R R S S S S NA 
164 20545 OP 3179 23 F OG Vaginitis HVS E.faecalis NP NP NP S S S S S S S S R S S S S NA 
165 20632 OP 3181 42 M Medical OP 
Wound 
Infection 
Pus E.faecium NP NP NP S S S S S S S R R S S S S S 
166  20784 OP 3185 74 M Medical OP 
Wound 
Infection 
Pus E.faecalis NP NP P S S S S S S S S S S S S S NA 
167  20138 OP 3203 21 F OG Vaginitis HVS E.faecalis NP P NP S S S S R S S S S S S S S NA 
168 20794 IP 3230 27 F Burns Ward 
Burns 
Wound 
Wound Swab E.faecalis NP NP P R R R R R R R R R S S S S NA 
169 20873 IP 3233 75 M Surgery 
Diabetic 
Foot 
Pus E.faecium NP NP P R S S R S S S S S S S S S S 
170 17939 IP 3286 68 M Surgery 
Diabetic 
Foot 
Pus E.faecium NP P NP R S R R R R R R S S S S S S 
171 17449 IP 3314 60 F Surgery 
Wound 
Infection 
Pus E.faecalis P NP P R R S R R R R R R S S S S NA 
172 18003 IP 3315 48 M Surgery 
Diabetic 
Ulcer 
Pus E.faecium NP NP P R S S R R R S R R S S S S S 
173 119 IP 3335 58 M Surgery 
Wound 
Infection 
Pus E.faecium P NP P S S S S S S S S R S S S S S 
174   OP 3337 20 F OG Vaginitis HVS E.faecium NP NP NP R S S R R R S R R S S S S S 
175   OP 3362 22 F OG Vaginitis HVS E.faecalis NP NP NP R R S R S S S S S S S S S NA 
176 21276 IP 3372 55 M Surgery 
Diabetic 
Ulcer 
Pus E.faecalis P NP P S S S R S S S S S S S S S NA 
177 21667 IP 3380 40 F Surgery 
Wound 
Infection 
Pus E.faecium NP NP P R S R R R S S R R S S S S S 
178 21742 IP 3388 57 M Burns Ward 
Burns 
Wound 
Wound Swab E.durans NP NP NP R S S R S S S S R S S S S S 
179 21694 IP 3389 20 F Burns Ward 
Burns 
Wound 
Wound Swab E.faecium NP NP NP R R S R S S S S S S S S S S 
180 21559 IP 3390 1 
MC
H 
Burns Ward 
Burns 
Wound 
Wound Swab E.faecalis NP NP NP R R S R S S S S S S S S S NA 
181 20232 iP 3391 32 M Burns Ward 
Burns 
Wound 
Wound Swab E.faecalis NP NP P R R S S S S S S R S S S S NA 
182 21853 IP 3393 30 M Burns Ward 
Burns 
Wound 
Wound Swab E.faecium P NP P S R S S S S S S S S S S S S 
183 1073 IP 3394 55 M Burns Ward 
Burns 
Wound 
Wound Swab E.faecalis P NP NP R R S R S S S S S S S S S NA 
184 21432 IP 3401 32 F Burns Ward 
Burns 
Wound 
Wound Swab E.faecalis NP P NP R S S R S S S R S S S S S NA 
185 21273 IP 3408 55 M Surgery 
Diabetic 
Ulcer 
Pus E.faecalis P NP P R R R R R R S S S S S S S NA 
186 21793 OP 3414 21 F OG Vaginitis HVS E.faecalis NP NP NP S S S S S S S S S S S S S NA 
187 21991 IP 3415 24 F Burns Ward 
Burns 
Wound 
Wound Swab E.faecium NP NP NP R S S R S S S S S S S S S S 
188 17326 IP 3416 30 F Burns Ward 
Burns 
Wound 
Wound Swab E.faecium NP NP P R R R R R S S R S S S S S S 
189 20820 IP 3418 37 F Burns Ward 
Burns 
Wound 
Wound Swab E.faecium NP P NP R R R R R R R R S S S S S S 
190 20016 IP 3419 36 F Burns Ward 
Burns 
Wound 
Wound Swab E.faecalis NP P P R R S R S S S S R S S S S NA 
191 16487 IP 3421 53 F Burns Ward 
Burns 
Wound 
Wound Swab E.faecium NP NP P R S S R S R R S S S S S S S 
192 21969 IP 3422 4 FCH Burns Ward 
Burns 
Wound 
Wound Swab E.faecalis NP NP NP R S S R S S S S S S S S S NA 
193 21688 IP 3426 30 F Surgery 
Wound 
Infection 
Pus E.faecalis P NP P R S S R S S S S R S S S S NA 
194 21309 OP 3433 30 F OG Vaginitis HVS E.faecalis NP NP NP R S S R S S S S R S S S S NA 
195 22056 IP 3445 29 M Burns Ward 
Burns 
Wound 
Wound Swab E.faecium NP NP NP R S S R R S S S S S S S S S 
196  21484 OP 3447 26 F OG Vaginitis HVS E.faecium NP NP NP R R S R R S S S S S S S S S 
197 21648 IP 3449 7 FCH Pediatrics 
Wound 
Infection 
Pus E.faecalis NP NP P S S S R S S S S S S S S S NA 
198 21884 IP 3450 3 FCH Pediatrics 
Wound 
Infection 
Pus E.faecalis P P P R S S R S S S S S S S S S NA 
199 22084 OP 3451 27 F OG Vaginitis HVS E.faecalis NP NP NP R S S R S S S S S S S S S NA 
200 21174 IP 3514 25 F BICU 
Burns 
Wound 
Wound Swab E.faecalis NP NP NP R S S R R S S S R S S S S NA 
201 22732 IP 3516 20 F BICU 
Burns 
Wound 
Wound Swab E.faecalis NP P P S S S S R S S S S S S S S NA 
202 22601 IP 3517 25 M BICU 
Burns 
Wound 
Wound Swab E.faecium P NP NP R R R R R R R R R R S S S S 
203 21154 IP 3518 40 F BICU 
Burns 
Wound 
Wound Swab E.faecalis NP NP NP R S S R R S S S S S S S S NA 
204 116862 OP 3520 56 M Surgery 
Diabetic 
Ulcer 
Pus E.faecalis P NP P R R R S R R R R R S S S S NA 
205 20825 IP 3524 36 M Ortho 
Wound 
Infection 
Pus E.faecium NP NP NP R R R R R R R R R S S S S S 
206 181673 OP 3527 60 M Surgery 
Diabetic 
Ulcer 
Pus E.faecium NP NP P S S S S S S S S S S S S S S 
207 484/15 IP 3532 45 M 
Plastic 
Surgery 
Wound 
Infection 
Pus E.faecium P P NP R R S R R S S S R S S S S S 
208 16238  IP 3548 33 M BICU 
Burns 
Wound 
Wound Swab E.faecium NP NP NP R R S R R R R R R S S S S S 
209 16351 IP 3564 11 FCH BICU 
Burns 
Wound 
Wound Swab E.faecium NP NP NP R R R R R R R R R S S S S S 
210 3182 IP 240 49 F IMCU 
Septicemi
a 
Blood E.faecium P P P R R S R R R S R R S S S S S 
211 2615 IP 247 6D FCH NICU 
Septicemi
a 
Blood E.faecalis P P P R R S S R R S R R S S S S NA 
212 2971 IP 280 48 F Medicine  
Fever For 
Evaluation 
Blood E.faecalis NP NP NP R R R R R R R R R S S S S NA 
213 3779 IP 307 
12 
D 
MC
H 
NICU 
Septicemi
a 
Blood E.faecium NP NP NP R R S S R S S S R S S S S S 
214 4030 IP 327 6 
MC
H 
Pediatrics 
Fever For 
Evaluation 
Blood E.faecalis NP NP P R R S S S S S R S S S S S NA 
215 4458 IP 395 43 F BICU 
Burns 
Wound 
Blood E.faecium NP NP P R R S S S S S R R S S S S S 
216 4490 IP 397 36 F Burns Ward 
Burns 
Wound 
Blood E.faecalis NP NP P R R S S S S S S R S S S S NA 
217 250 IP 457 70 F Nephrology 
Diabetic/
UTI 
Blood E.faecium NP NP P R R R R R R R R R S S S S S 
218 5525 IP 553 
13 
D 
FCH NICU 
Septicemi
a 
Blood E.faecalis NP P P R R S S R R S R R S S S S NA 
219 6160 IP 555 3D  FCH NICU 
Fever For 
Evaluation 
Blood E.faecium NP NP NP R R S S R S S R R S S S S S 
220 5739 IP 559 7D  FCH NICU 
Septicemi
a 
Blood E.faecalis P NP P R R S R R R R R R S S S S NA 
221 6418 IP 575 22 F OG 
Fever For 
Evaluation 
Blood E.faecium NP NP NP R R R R R R R R R S S S S S 
222 6291 IP 583 7D  FCH NICU 
Fever For 
Evaluation 
Blood E.faecalis NP NP NP S S S S S S S R R S S S S NA 
223 7049 IP 633 60 M Medicine 
Renal 
Calculi 
Blood E.faecalis NP NP P R R R R R R R R R S S S S NA 
224 7436 IP 634 24 M Medicine 
Diabetes/
UTI 
Blood E.faecalis P NP P R R R R R R R R R S S S S NA 
225 8145 IP 725 32 F BICU 
Wound 
Infection 
Blood E.raffinosus NP P NP R R S R S S S S R S S S S S 
226 10473 IP 932 32 F BICU 
Wound 
Infection 
Blood E.faecium NP NP NP R R S S R R S R R S S S S S 
227 11173 IP 958 38 F Medicine 
Fever For 
Evaluation 
Blood E.faecalis NP NP NP R R S S R S S R R S S S S NA 
228 11578 IP 961 
10
D  
FCH NICU 
Septicemi
a 
Blood E.faecalis P NP P R R S S R R S R R S S S S NA 
229 12258 IP 989 7D FCH NICU 
Septicemi
a 
Blood E.faecium P P P R S R R S S S R R S S S S S 
230 10507 IP 1013 37 M BICU 
Wound 
Infection 
Blood E.faecalis NP NP P R R S R R R S R R S S S S NA 
231 13221 IP 1081 37 M Medicine UTI Blood E.faecalis P P NP R R S R S S S R R S S S S NA 
232 14749 IP 1166 64 M Medicine 
Fever For 
Evaluation 
Blood E.faecalis NP NP NP R R S R R R S R R S S S S NA 
233 17203 IP 1319 20 M Medicine 
Diabetes/
UTI 
Blood E.faecium NP NP NP S R S S R S S R R S S S S S 
234 16857 IP 1328 10 
MC
H 
PICU 
Septicemi
a 
Blood E.faecalis NP NP P R R S R R R S R R S S S S NA 
235 21078 IP 1593 63 F Medicine 
Diabetic 
Foot 
Blood E.faecium P NP P R S R R S S S S S S S S S S 
236 21493 IP 1654 23 F Urology POI Blood E.faecalis P NP P R R R S R R S R R S S S S NA 
237 22175 IP 1692 40 M IMCU 
Diabetes / 
UTI 
Blood E.faecium NP P P R R S R R S S S S S S S S S 
238 24265 IP 1907 32 M IMCU 
Septicemi
a 
Blood E.faecalis P P P R R R R R R R R S S S S S NA 
239 15267 IP 2048 54 M Ortho 
Septicemi
a 
Blood E.faecium P P P R S R R R R R R R R R S S S 
240 26702 IP 2115 35 M BICU 
Wound 
Infection 
Blood E.faecium P P P R R R R R R R R R S S S S S 
 
